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The longitudinal muscle layer in gut is the functional
opponent to the circular muscle layer during the peristalsis
reflex.

Differences in innervation of the layers allow for the

contraction of one layer that corresponds with the simultaneous
relaxation of the other, enabling the passage of gut contents in
a controlled fashion.

Differences in development have given the

cells of the two layers differences in receptor populations,

membrane lipid handling, and calcium handling
profiles/behaviors.

The kinase signaling differences between

the two layers is not as well characterized.

Upon activation of

cells from the circular muscle layer, it is known that Rho
kinase and ERK1/2 promote contraction, while CaMKK/AMPK and
CaMKII perform inhibitory/self-inhibitory roles.

Such behaviors

are poorly understood in the longitudinal muscle layer.
In longitudinal muscle strips, we measured muscarinic
receptor-mediated contraction following incubation with kinase
inhibitors.

Upon comparison to control, contributions of Rho

Kinase and ERK1/2 were similar to those seen in circular muscle.
Inhibition of both of these enzymes leads to diminished
contraction.

However, CaMKK/AMPK and CaMKII have effects in

longitudinal muscle opposite to their regulation in circular
muscle – their inhibition also diminishes the contractile
response.

These contractile data from strips were supported by

immunokinase assay measurements of MLCK activity from strip
homogenates with and without kinase inhibition.

Therefore, we

suggest that the activities of CaMKK/AMPK and CaMKII in
longitudinal muscle are indeed different from their regulatory
roles in circular muscle, perhaps a consequence of the different
calcium handling modalities of the two muscle types.

INTRODUCTION
Function of Gut
Simply, the gut is a muscular tube that allows for the intake,
processing, absorption, and elimination of solid and liquid
nutrients.

The coordination of these roles involves the varied

chemical and mechanical abilities of the gut.

These abilities

in turn require numerous control mechanisms to maintain proper
function.

Gut as Agent of digestion/absorption/defense
The primary role of the gut is acquisition of necessary
nutrients for the maintenance of overall structural integrity
and energy supply, fueling the metabolic processes of the body.
As food and drink are ingested, regions of the gut play specific
roles in the mechanical and chemical breakdown of food
(digestion).

Mechanically, the muscular tube can collapse upon

its contents, physically compressing them to render the contents
into smaller pieces, leading to a suspension (or emulsion) of
the various ingested substances.

Different types of mechanical

activity ensure both this disassembly of ingesta and the
coordinated movement of ingesta through the gut, where a variety
of place-specific chemical processes can occur [1].
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Chemically, the gut releases agents into its lumen, where
mixing with the contents leads to chemical reactions that reduce
large polymer molecules (e.g. starches, proteins, triglycerides)
into smaller constitutive pieces (e.g. sugars, peptides, fatty
acids). This chemistry facilitates the absorption of these
ingested materials by non-muscular components.

The epithelium

facing the lumen possesses membrane bound enzymes that offer
final digestion of proteins and carbohydrates and the absorption
into the cells of the epithelium.

Lipid digestion products also

enter the epithelial cells by diffusion.

After entry into the

cells, the absorbed nutrients enter the blood stream as gut
tissue is highly served by both the circulatory and lymphatic
systems.

Digestion products that remain unabsorbed continue

passage through the gut for elimination from the organism.
The gut interior is contiguous with the external environment
and possesses considerable surface area.

Because of its high

exposure, the gut has intricate immunological roles and
abilities to prevent introduction of harmful substances or life
forms into the body.

These functions are carried out by cells

or tissues that are distinct from the cells or tissues charged
with the mechanical and chemical duties already mentioned.
These cells and tissues offer regulation of gut function,
including motility, and their roles in maintenance of basic

2

functions is beginning to find appreciation in the
literature[2].

Under normal conditions, beyond immunological

threat, the gut itself possesses sensory functions upon its
exposure to contents of a meal.

Such sensory cells can perhaps

feed into a control network that manipulates motility,
secretory, and absorptive behaviors.

Altered behaviors could

optimize the efficiency of the gut when the contents warrant, or
prevent inefficiency when stimuli communicate harmful or
wasteful contents [3, 4].

Transit of Gut Contents
The movement of contents through the gut and the mechanical
treatment of contents while inside the lumen are critical for
efficient absorption of nutrients.
motility accomplish these roles.

Two general patterns of gut

Both motility patterns require

coordinated activity of the two muscular layers of the gut, the
circular muscle layer and the longitudinal muscle layer.
The circular muscle layer consists of muscle cells oriented
around the circumference of the gut lumen, forming adjacent
rings of muscle that extend throughout the gut.

Upon local

activation of these cells, the circular muscle tissue contracts,
and these muscular rings decrease their diameter and therefore
the caliber of the gut lumen.

The longitudinal muscle layer is

comprised of cells oriented along the long axis of the gut,
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parallel to the overall direction of the movement of contents.
Upon local activation, the contraction of longitudinal muscle
causes the gut lumen to increase its diameter in a manner that
shortens the gut at that location.

Because of their opposing

actions on the gut lumen, the two muscular layers will not
normally activate at the same location simultaneously. However,
when these opposing actions occur at adjacent locations, the
contents of the lumen can be manipulated in a controlled fashion
[5].

Gut Anatomy
Gut structure varies along the length of the canal, but
generally possesses a consistent layered organization.

Outer

layers provide for structural integrity and muscular activity,
and inner layers secrete substances into the lumen and have
mechanisms that allow for the absorption of ingested nutrients.
In addition, there are neural connections and vascular pathways
throughout all gut tissue.

Gross Anatomy
The innermost layer of the gut is the mucosa, containing both
the epithelial cells necessary for final digestion and
assimilation of the ingested material, and the lamina propria, a
layer of connective tissue with capillaries and lacteals to
convey absorbed nutrients.

In addition, the mucosal layer
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possesses glands able to secrete substances into the gut lumen,
cells with sensory capabilities, and the muscularis mucosae, a
thin layer of smooth muscle that aids in enhanced contact of the
epithelium with luminal contents as a result of its contractile
function.

Outside of the mucosal layer lies the submucosa,

another layer of connective tissue that possesses connections to
the vasculature, inflammatory cells, and in some cases, glands.
The submucosa contains a neural plexus, the submucosal plexus
which has interconnections within the nervous system of the gut
(enteric nervous system), as well as connections to the
autonomic nervous system.

This submucosal plexus is important

in controlling the secretory functions of the mucosa through
innervation of the epithelium, and may play a role in the
coordination of muscularis mucosae and muscularis externa
activity with secretory activity[6].
External to the submucosa is the circular muscle layer, a
layer of smooth muscle cells oriented circumferentially to the
central axis of the gut lumen.

When cells in this muscle layer

contract, the overall effect is the narrowing of the lumen at
this location.

When properly coordinated, this narrowing of the

lumen can propel the luminal substances within forward in the
gut.

This contraction can also mix the contents of the lumen at

the contraction locale.

Because of its muscular activity, this
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layer also contains blood vessels and neural connections, but
does not contain the nerve bodies themselves[7]. Continuing
outward radially, the adjacent layer contains neurons and
organized connections among these neurons within the enteric
nervous system, as well as external connections to the autonomic
nervous system.

This myenteric plexus plays a chief role in

controlling the muscular activity of the circular muscle layer
beneath it, and the longitudinal muscle layer above it[8].

The

longitudinal muscle layer consists of smooth muscle cells
oriented in parallel with the long axis of the lumen.

The

longitudinal muscle layer is substantially thinner than the
circular muscle layer and varies in its receptor population,
calcium handling, and signaling chemistry[9].

When longitudinal

muscle contracts, the lumen of the gut is dilated at the
contraction site and the gut shortened, in contrast to the
actions of the circular muscle.

The neural connections provided

by the myenteric plexuses between the longitudinal and circular
muscle layers coordinate activity ensuring that longitudinal
muscle and circular muscle do not simultaneously contract at the
same location in gut[10, 11].
Beyond the longitudinal muscle layer there exists a serous
membrane, the serosa, which serves as an outer containment
membrane for the gut tube.

The epithelial cells of this layer
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secrete a serous fluid to lubricate the outer surfaces of the
gut.

The layers of the gut are depicted in Figure 1 [12].

7

Figure 1. Structure of the Gut Wall. Adapted from Furness.
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Cell Types
Two cell types dominate the population of gut cells – smooth
muscle cells and epithelial cells.

The smooth muscle cells,

located in the circular muscle layer and longitudinal muscle
layer, are responsible for motility patterns of the gut, both
the propulsive pattern and the non-propulsive segmentation
pattern.

Smooth muscle cells also are found in the muscularis

mucosa layer, aiding in exposure of the epithelial cells with
the gut contents[6].
The epithelial cells are critical for the absorption of
nutrients for the luminal contents.

Epithelial cells also

possess enzymes necessary for the final digestion of the same.
Beyond these two dominant cell types, there exist several types
of enteroendocrine cells that serve sensory/control functions
through monitoring of gut contents and relaying of hormonal
signals that may affect overall motility, secretory, and
absorptive action[4, 13].
The presence of immune cells and tissue within the gut is
extensive, a consequence of exposure of the tremendous surface
area of gut mucosa to the environment.

As such, the entry into

the body of most antigens occurs through this epithelial
barrier.

Defending this barrier from pathogenic invasion, while

recognizing critical resident flora, requires an immune system
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distinct from the rest of the body[14].

The gut immune system

initiates responses that cooperate with the general immune
system.

The gut is also highly served by lymphatic vessels,

which play a role in lipid absorption.

Because of the size and

importance of the gut as an immune organ, it possesses a
population of immune cells greater than the spleen, skin, and
lymph nodes combined[2].

Innervation
The enteric nervous system (ENS) is contained within the two
anatomical plexuses, the myenteric and submucosal plexuses.
These structures provide the motor control for the muscle
layers, secretory control of the mucosal layers, and control for
the circuitry offered by a variety of sensory mechanisms.

The

enteric nervous system can stand alone, performing its duties
independent of the central nervous system, but is normally
modulated by inputs from the autonomic nervous system.
Parasympathetic influences upon the ENS originate in the vagal
nuclei of the brain stem that synapse upon the ENS plexus of the
esophagus, stomach, and upper intestine, and also from sacral
parasympathetic nuclei, synapsing upon the plexuses of the
colon[15].

Parasympathetic activity promotes overall gut

function, exciting extant motor and secretory pathways.
Sympathetic activity incident on the gut travels from
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prevertebral ganglia onto the ENS plexuses.

Such activity

reduces the actions of the ENS overall, slowing motility and
secretion.

Sympathetic activity also excites sphincteric

muscle, preventing organized movement of ingesta through the
gut[16].
As in the central nervous system, the ENS consists of not only
neurons of various types, but also glial cells that protect and
maintain the intricate networks of neurons, as well as providing
modulatory input to neurons of all types.

Complicated

interconnections of motor and sensory neurons and interneurons
allow for local control of the sophisticated motor behaviors of
the gut.

As mentioned, circular muscle contraction must occur

orad to gut contents (with longitudinal relaxation), and
circular muscle relaxation caudad to the contents (with
longitudinal contraction).

Differences in the innervation and

functions of the circular and longitudinal muscle layers allow
for this coordination.
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ICCs/Fibroblast-like cells
In addition to the connections displayed in the above diagram,
other cells participate in the shaping of electrical activity.
The interstitial cells of Cajal (ICC) are neuron-like
interstitial cells located through the gut.

These cells are

capable of depolarizing themselves to threshold potential and
initiating depolarization in surrounding gut muscular tissue.
The mechanism of their self-depolarization, involving
intracellular Ca stores and mitochondrial Ca uptake is
inherently rhythmic, and this rhythmic depolarization is seen
within the gut musculature that the ICCs influence.

Beyond the

basic rhythms which are specific to specific gut regions, the
overall excitability of ICCs can be affected by
stretch/distention, furthering their contribution to motility,
as increased frequency of firing promotes both segmentation and
peristaltic behaviors[17, 18].

Microscopic studies using

electrically sensitive dyes show that the ICCs may play a role
in the electrical coupling of the longitudinal and circular
muscle layer.

This connection is specialized to promote

coordination without destroying the intrinsic electrical
identity of the two layers [19, 20].

Another cell type, the

fibroblast-like cell, appears to co-exist with the ICCs in the
plexus and muscle layers.

They possess great similarity with

ICCs, but are reported to be distinguishable via microscopy.
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These cells are in close proximity to terminals of enteric
neurons, ICCs, and smooth muscle cells.

Their high current

densities and apparent gap junction formation with SMC loosely
suggest that fibroblast-like cells may be involved in a
modulation role in transmission to and perhaps between the
muscle layers [21-23].

These results, however, remain highly

controversial.

Innervation of Circular and Longitudinal Muscle
From the neural plexus, processes travel to the muscle layers.
However, the population of nerves that are efferent to the
longitudinal muscle layer and the circular muscle layer are
different in type and quantity.

The motor neurons incident upon

longitudinal muscle are overwhelmingly excitatory and the vast
majority of these excitatory neurons contain acetylcholine as a
neurotransmitter.

Approximately half of these neurons can also

possess excitatory peptide neurotransmitters, such as the
tachykinins substance P and neurokinin A[24].
The lack of a robust population of neurons with inhibitory
neurotransmitters suggests that inhibition of longitudinal
muscle is mediated through the control of these existing
excitatory pathways.

The interneurons that modulate the

excitatory motor neurons of longitudinal muscle possess
receptors for typically inhibitory neurotransmitters, such as
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vasoactive intestinal peptide (VIP) and nitric oxide (NO)[25].
However, these interneurons excite upon exposure to these
typical inhibitory agents, and stimulate the release of Ach and
tachykinins from the downstream motor neurons.

Whereas VIP and

NO would promote relaxation if directly incident upon muscle
cells, when incident upon interneurons, contraction is fostered.
It is thought that these interneurons, specific to longitudinal
muscle, contribute to the coordinated inverse behaviors of
circular and longitudinal muscle at the specific site of gut
activity.
In circular muscle, a more direct, and yet more involved,
scheme exists.

The muscle tissue itself is densely innervated

with both excitatory and inhibitory neurons.

Inhibition of

circular muscle cells can be elicited by direct neuronal release
of inhibitory neurotransmitters, whereas a specialized
interneuron is necessary for the majority of longitudinal muscle
inhibition.

The receptor population in circular muscle is

richer in variety and number.

Circular muscle cells possess

receptors that longitudinal muscle does not, including opioid
receptors, somatostatin receptors, and neuropeptide Y2 and Y4
receptors [26-28].

No receptors have been identified that exist

in longitudinal muscle cells that do not exist in circular
muscle cells.

Circular muscle can be signaled to contract or
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relax by a variety of neurotransmitters and circulating agents,
both peptide and non-peptide in nature.

The control of

contraction of longitudinal muscle is primarily cholinergic, and
the control of relaxation in longitudinal muscle is responsible
to a unique subset of myenteric interneurons which do not
innervate circular muscle.

Muscle Contraction
Muscle activity is driven by the interaction of the proteins
actin and myosin.

Actin maintains two primary roles in the

cell, forming both the microfilaments that are critical to
cytoskeletal structure and the thin filaments in muscle cells
that provide structure against which the motor protein myosin
can exert force.

The alpha isoform of actin is the actin

associated with muscular contraction, whereas the beta and gamma
isoforms of actin play more important roles in the cytoskeletal
arrangement[29].

There are several classes of myosin proteins,

most playing a role in a form of movement, ranging from muscular
contraction to vesicular transport.

Myosin class II is the

useful form in muscle, interacting with actin to generate
force[30].
Myosin itself is composed of several “chains”, domains of this
very large protein.

The heavy chains are important in muscle

contraction, and the light chains important in structure and
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regulation of the activity of the heavy chains.

The interaction

of actin and myosin facilitates the inherent ATPase activity of
the heavy chains of myosin.

Regulation of myosin activity and

muscle contraction is accomplished by either the regulation of
the association of actin with myosin or by direct manipulation
of the catalytic activity of the myosin protein.

The three

general types of muscle - skeletal, cardiac, and smooth muscle
each possess differing mechanisms to achieve this
regulation[31].

However, all mechanisms involve manipulation of

intracellular levels of free calcium which precede any actions
of actin and myosin, and all mechanisms involve specific
proteins that interact directly with either actin or myosin.

Skeletal
In skeletal muscle, a nerve impulse is transmitted to a muscle
fiber by means of the neuromuscular junction.

The action

potential travels down the sarcolemmal membrane and into the Ttubules that penetrate into the body of the muscle fiber.
Dihydropyridine receptors (voltage-gated calcium channels) are
activated by the depolarization of the action potential upstroke
and are electrically coupled to the ryanodine receptors on the
sarcoplasmic reticulum.

Ryanodine receptor activation leads to

release of calcium from the sarcoplasmic reticulum, and
intracellular calcium is elevated.
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This free calcium binds to

the protein troponin, which is in a protein complex with
tropomyosin.

In low calcium (relaxed) state, the tropomyosin

within this complex is positioned in a manner that prevents the
binding of actin and myosin, preventing contraction.

When

calcium is bound to troponin, however, the troponin-tropomyosin
complex undergoes a conformational change that removes the
steric inhibition of actin by tropomyosin, exposing the active
sites on actin, and permitting actin-myosin interactions.

The

termination of contraction occurs as the intracellular calcium
is reduced through the activity of Ca2+ ATPases on the
sarcoplasmic reticular membrane. Unbound troponin reinstates the
inhibition of actin sites by tropomyosin.

Cardiac
Cardiac muscle contraction is similar to skeletal muscle in
the manner of troponin-tropomyosin-actin interactions.

The

mechanism that leads to the increase of intracellular free
calcium that enables these reactions is profoundly different.
An action potential on the membrane of a cardiomyocyte is not of
neural origin, but from specialized muscle cells at an alternate
location in the heart.

The depolarization that led to calcium

channel activation (and ryanodine receptor activation) in
skeletal muscle leads to actual calcium entry through similar
channels in heart.

This calcium entry triggers a large release
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of calcium from sarcoplasmic reticular stores (Ca-induced Carelease), and this sarcoplasmic calcium is responsible for
troponin binding and the removal of inhibition from actin.

The

contraction of cardiac muscle is dependent upon the entry of
extracellular calcium, and the strength of contraction is a
consequence of the amount of calcium influx and its
modulation/activation of the ryanodine receptors[32].
Relaxation is similar, involving the uptake of calcium into and
its sequestration in the cardiac sarcoplasmic reticulum.

Smooth
Smooth muscle contraction has few similarities to the
excitation-contraction coupling mechanisms in striated muscle.
Ultimately, contraction is permitted when the regulatory light
chains of myosin are appropriately phosphorylated.

There is no

steric interference of the actin and myosin filaments as in
cardiac and skeletal muscle; troponin is absent in smooth
muscle, but the thin filaments protein calponin and caldesmon
have been implicated in similar regulatory roles[33].
The phosphorylation of the myosin regulatory light chain at a
serine residue at position 19 is sufficient to cause crossbridge formation and cycling, ATP hydrolysis, and muscle
contraction[34].

Phosphorylation of the regulatory light chain

in striated muscle does occur, but it is neither sufficient nor
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necessary for contraction as in smooth muscle.

Such

phosphorylation in striated muscle, will, however, increase
force production and speed of contractions[35].
Smooth muscle has a more dynamic control mechanism than
striated muscle, as the phosphorylation level of myosin is
affected by the action of scores of kinases and phosphatases.
Furthermore, other protein targets exist within smooth muscle
that can shape the forces developed by the actin-myosin
interaction dynamics, independent of the myosin phosphorylation
level.

Investigation of those other mechanisms in general

smooth muscle and the differences among smooth muscle types are
the ultimate goal and drive of this study.

Regulation of smooth muscle contraction
As stated, the contraction of smooth muscle is driven by the
control of the phosphorylation level of the 20 kDa regulatory
light chain of myosin II (MLC20). Membrane receptor activation
leads to the initiation of second messenger signaling cascades,
and, ultimately, an increase in intracellular calcium.

The

calcium binding protein calmodulin complexes with the sudden
increase in intracellular calcium, and a host of Ca2+/calmodulin
dependent processes are launched.

Of primary interest is the

Ca2+/calmodulin-dependent enzyme myosin light chain kinase
(MLCK), a dedicated protein kinase of which MLC20 is its only
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substrate[35].

Phosphorylation levels of MLC20 rise and the

uninhibited actin/myosin interactions initiate contraction.
Phosphorylation levels of MLC20 can remain high even as the
initial Ca2+ transient diminishes, as MLC20 is targeted by kinase
other than MLCK.

In addition, maintained phosphorylation levels

and contractile force can be achieved through inhibition of
myosin light chain phosphatase (MLCP), an enzyme dedicated to
the dephosphorylation of MLC20. Ultimately, relaxation occurs as
the phosphatase activity predominates and phosphorylation levels
of MLC20 fall, reducing the interaction and enzymatic activities
of actin/myosin[36].

Receptors/Membrane-Mediated Processes
A large variety of receptor types enable a wider variety of
chemical agents to initiate or modulate smooth muscle
contraction.

These agents via membrane receptor-mediated

processes will affect muscle tone through either the
manipulation of calcium levels (and the Ca2+-dependent processes
MLCK and MLCP), the activation of enzymes outside of the
standard Ca2+-dependent pathways that affect MLC20 phosphorylation
levels (critical for sustained contraction and relaxation), or
through the manipulation of the motor proteins themselves
(altering their affinities for each other or for their assigned
enzyme effectors)[37].

The enteric nervous system is capable of
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generating numerous excitatory agents, specific to location,
motility patterns, and in response to perceived stimuli[38].
The smooth muscle cells themselves may release agents that can
elicit local responses, and endocrine agents may bring
modulation through the general circulation[39].
Ligands for membrane receptors in gut can be classic nonpeptide neurotransmitters (acetylcholine, dopamine), peptide
transmitters (somatostatin, vasoactive intestinal peptide),
peptide hormones (cholecystokinin), or atypical ligands with
plant-based origins that arrive by ingestion and diffusion to
the muscle layers[3, 13, 27, 40-43].

Receptor profiles for

smooth muscle vary among types and even vary within the same
type at different locations.

Also, identical ligand-receptor

pairs can elicit differing effects in alternative locations of
smooth muscle [40, 44, 45].

Most receptors responsible for

contraction in smooth muscle are coupled to transmembrane Gproteins, although receptor tyrosine kinase pathways are
important to growth factor-induced contraction [46, 47].

These

G-proteins then activate second messengers or directly activate
specific kinase cascades in the cytosol.

The G-proteins,

associated second messengers, and kinase cascades are often
specific to smooth muscle type and function, and may differ
within the same organ system[45].
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Calcium
The elevation of intracellular calcium is physiologically
necessary for the initiation of contraction in smooth muscle.
The primary source for this calcium is the sarcoplasmic
reticulum of the smooth muscle cell.

Within the SR of smooth

muscle cells, calcium is primarily bound to the sequestering
protein calreticulin, and not calsequestrin as in striated
muscle [48, 49].

Preceding smooth muscle contraction, receptors

on the SR membrane must be activated so that stored calcium may
be released into the cytosol.
smooth muscle types.

Here, differences exist between

In circular smooth muscle of the gut, IP3

receptors exist on the SR membrane and as levels of the second
messenger rise, these receptors are activated, and calcium
release channels open.

In longitudinal muscle of the gut, IP3

receptors are absent from the SR – external calcium entry is the
signal to ryanodine receptors for SR calcium release[50].

This

mechanism of Ca2+-induced Ca2+ release bears strong resemblance to
cardiac muscle excitation-contraction coupling, and is specific
to longitudinal gut smooth muscle.
The entry of calcium from the extracellular space is another
mechanism of control.

In longitudinal muscle, this entry is

coupled to the calcium release from the SR that permits
contraction.

In both circular and longitudinal muscle, the

entry of calcium is an important component of the electrical
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excitability of the muscle.

In both gut muscle types, the

voltage-dependent calcium channel (VDCC) CaV1.2 is expressed[51].
Upon depolarization of the sarcolemmal membrane by agonistinduced inward currents (or local electrotonic depolarization),
these channels carry the inward calcium current responsible for
the action potential upstroke[52].

The gating behavior and

sensitivities of these channels are regulated by various kinases
upon receptor activation, inflammation, and a host of cellular
metabolic events [53-55].

The calcium that enters via these

channels is coupled to SR calcium release in longitudinal
muscle, as well as the enhancement of kinase pathway activation,
gene expression, and energy metabolism in both muscle types [56,
57].

There is also significant interplay between calcium entry

through these VDCCs and the membrane ion channels (KCa and ClCa)
responsible for cellular repolarization [58, 59].

MLCK
Myosin light chain kinase (MLCK) is a dedicated serinethreonine kinase that has the 20 kDa regulatory light chain of
myosin II (MLC20) as its sole substrate.

Upon binding with the

calcium-calmodulin complex, MLCK phosphorylates MLC20 at serine
19, permitting the actin-myosin interaction that allow for
smooth muscle contraction.

Also, phosphorylated MLC20 (MLC20-p)

is involved in other processes related to cytoskeletal
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manipulation such as motility, apoptosis, and secretion[35].
Many studies have shown that MLC20 can be phosphorylated by other
kinases, and this phosphorylation is important during the
sustained contraction of tonic smooth muscle, but it is the
phosphorylation of MLC20 by MLCK that is the predominant effector
of initial contraction[34, 60, 61].

The activity of MLCK itself

can be affected by its phosphorylation at several site; kinases
that phosphorylate can increase or decrease MLCK activity, and
may do so by either altering the rate of enzyme activity or the
affinity of MLCK for Ca2+-calmodulin [62-66].

MLCP
Myosin light chain phosphatase (MLCP) is the opposing enzyme
to MLCK, removing the phosphate from Serine 19 on MLC20.

It is a

trimer composed of protein phosphatase 1c-, the myosin
phosphatase target subunit 1 (MYPT1), and a small 20kDa unit
M20[67].

The PP1 family of enzymes is expressed widely in

tissues and is a non-specific serine/threonine phosphatase.

PP1

enzymes are typically bound to a targeting subunit to direct
this non-specific enzymatic action here by MYPT1.

MYPT1 targets

the phosphatase subunit to MLC20, while increasing the
specificity of PP1c- through a conformational change that occurs
when bound to MYPT1[68].

The M20 subunit is of unknown

function.
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The overall level of MLC20 phosphorylation is closely tied to
the activity level of these two opposing enzymes,
notwithstanding the MLCK-independent phosphorylation of MLC20.
As MLCK activity can be modified by select kinases, MLCP can
also be reduced in its activity by interaction with two of its
subunits.

When the subunit MYPT1 is phosphorylated at threonine

696 (human), the phosphatase subunit can no longer be directed
properly to its myosin target [69]. Rho kinase was the first
studied kinase to phosphorylate MYPT1 in this manner, but
several kinases have been identified as effectors of MYPT1.
Some phosphorylate in a manner similar to Rho kinase, and others
target residues that prevent the Rho Kinase-like inhibition[70].
The wide range of kinases that target MYPT1 invites discussion
of perhaps a greater role in cellular functions for MLCP[30].
The phosphatase subunit PP1c- has an endogenous inhibitor, Ckinase potentiated protein phosphatase-1 inhibitor (CPI-17).
The phosphorylation of CPI-17 at serine 12 and threonine 38
enabled its blocking of PP1c- activity and this phosphorylation
is performed by many of same kinases that phosphorylate MYPT1
[71-75].

Initial/Sustained
Contraction in some smooth muscles type is biphasic – an
initial transient contraction of relatively high amplitude,
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followed by a lowering of tone to a reduced but sustained
contraction.

Other muscle types maintain moderate levels of

tone for extended periods of time.

An initial contraction and

the initial partial decline agree with the transient change in
intracellular calcium.

Following the release of calcium by any

specific mechanism, MLCK activity will increase as it binds to
calcium-calmodulin complexes.

Following the transient increase,

calcium uptake by the SR reduces intracellular calcium levels to
pre-contraction values.

Tone in the muscle can still be

maintained at a lower degree despite a calcium level that would
not alone develop such tone.

This phenomenon of elevated tone

with low calcium is termed calcium sensitization [36, 76].
Two general mechanisms are responsible for sustained tone.
Calcium sensitization has been studied extensively in
preparations where calcium levels are held constant.

Studies

have shown that both MLCK activity may be altered at constant
calcium and that MLC20 can be phosphorylated by kinases other
than MLCK at all levels of calcium[44, 61, 77-79].

These Ca2+-

independent processes are partially responsible for the enhanced
tone of the sustained phase of contraction.

MLC20

phosphorylation levels are also affected by activity of MLCP,
and inhibition of this phosphatase activity contributes to
maintained tone.

Both inhibitors of MLCP activity,
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phosphorylated CPI-17 and MYPT1, have been implicated in the
sustained phase, either individually or in concert [80-82].
CPI-17 and MYPT1 are expressed to different degrees across
smooth muscle types, and this ratio of expression can be
connected to general phasic (initial and sustained contractile
behavior) or tonic (extended sustained contractile with no
initial peak) motility patterns[83].

Many kinases that offer

Ca-independent phosphorylation of MLC20 (through either enhanced
MLCK activity or direct phosphorylation) also phosphorylate the
inhibitors of MLCP[39, 81].

Agonists that cause standard Ca-

dependent increases in MLCK activity may also promote
phosphatase inhibition through the same or alternate subtypes of
their receptors [84, 85].
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Circular Muscle
Receptors/G-Proteins/Second Messengers
Circular muscle in gut expresses an extensive array of
receptors for both neurotransmitters released by the enteric
nervous system, agents from gut tissue, and agents in the
circulation.

Muscarinic receptors are in the greatest number,

with muscarinic type 2 (M2) outnumbering muscarinic type 3 (M3),
but only M3 is thought to participate directly in
contraction[86].

A majority of identified receptors operate

through G-proteins, but receptor tyrosine kinase activity has
been seen in intestinal muscle with exposure to members of the
growth factor family[87].

Though these effects can couple

downstream with cascades that start at G-proteins, they are
mainly seen during proliferation and may be primarily
pathophysiological in presence[88].
G-protein activation in circular muscle stimulates
phosphoinositide (PI) hydrolysis by members of the phospholipase
C (PLC) family.

The beta isoforms predominate in activity with

PLC-beta1 downstream of M3 activation (via Gq) and PLC-3
downstream of M2 activation (via Gi)[89].

Activation of M3 is

critical for contraction, and leads to hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5trisphosphate (IP3) and diacylglycerol (DAG)[90, 91].
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Both IP3

and DAG have downstream effects that shape contraction.

G-

proteins activated in circular muscle may also have downstream
effects of adenylate cyclase, Rho kinase, PI-3 kinase, and other
members of the phospholipase family[39].

It is, however, M3

activation leading to IP3 formation that is essential in the
initial contraction.

Activation of M2 has downstream effects on

contraction (primarily inhibitory), but mostly operate on a time
scale beyond the M3/IP3 consequences[84].

IP3/SR Ca release
With agonist-induced IP3 formation via PLC, IP3 receptors
(IP3R) are activated on the SR of circular muscle.

These

receptors are SR membrane calcium channels, have high affinity
for IP3, and are inhibited by heparin[92].

When IP3 binds to

these receptors, calcium stored in the SR is released into the
cytosol[93].

This transient increase in intracellular calcium

causes binding sites on calmodulin to be occupied, and the
calcium-calmodulin complexes then activate MLCK, initiating
contraction.

Other calcium dependent enzymes are also activated

which may modulate the activities of MLCK and MLCP.

The rise in

intracellular calcium is short-lived, as pumps on the SR
membrane re-accumulate the released calcium, and with the
actions of the cell membrane Ca2+-ATPases, restore the levels of
calcium to previous values.

These IP3 receptors/Ca channels are
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modulated by association with other receptors on the SR
membrane, protein kinases, and the level of intracellular
calcium that these channels manipulate.

All these effects can

shape the kinetics of release, and consequently the effects of
the calcium transient [58, 94-97].

Ca-Independence
Following the decline of the calcium transient, Ca-independent
processes allow for a degree of sustained tone to be maintained.
Ca-independent kinases such as Integrin-Linked Kinase (ILK) and
Zipper-interacting protein kinase (ZIPK) phosphorylate MLC20 in
manner similar to the Ca-dependent MLCK [98-100].

MLC20

phosphorylation levels are also kept at an elevated level by
inhibition of the myosin phosphatase, either through
phosphorylation of MYPT1 or CPI-17.

It is not uncommon for

agents to initiate the Ca2+-independent phosphorylation of myosin
while simultaneously inhibiting the phosphatase, nor it is
uncommon for pathways to activate both known mediators of
phosphatase inhibition [74, 75, 81, 82].

Relaxation
Relaxation is fostered when phosphatase activity exceeds
active MLC20 phosphorylation.

Both protein kinase A (PKA) and

protein kinase G (PKG) are implicated in the relaxation of
smooth muscle.

Inhibitory neurotransmitters such as VIP
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activate Gs proteins, increasing cAMP levels through adenylate
cyclase stimulation, and leading to increased PKA activity.

PKA

can target membrane ion channels leading to hyperpolarization,
phosphorylate upstream molecules to inhibit contractile
pathways, and directly phosphorylate MYPT1 in a fashion that
precludes its role as an inhibitor of MLCP [101-103].

Nitric

oxide (NO), another inhibitory transmitter, can elevate PKG
activity through stimulation of soluble guanylate cyclase.
Protein Kinase G has similar targeting as PKA to inhibit
contraction/promote relaxation, and has been shown definitively
also to phosphorylate CPI-17 at a site that precludes its
involvement in MLCP inhibition [72, 104, 105].

Whether PKA

targets CPI-17 directly to promote relaxation finds conflict in
the literature [101, 105].

Rho Kinase
Rho-associated kinase (Rho Kinase) is a serine-threonine
kinase widely expressed in tissues and implicated in a wide
array of cytoskeletal processes, including cell motility, cell
proliferation, neurite growth, and apoptosis[106].

Rho Kinase

is speculated to be a promising target in treatments of
Alzheimer’s disease, stroke, multiple sclerosis, and pain [107].
Its physiological interaction with cytoskeletal structures also
leads to a role in muscle contraction, and the inhibition of Rho
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kinase finds clinical uses in treatment of asthma and
hypertension [108-110].
Effects on contraction by Rho kinase mainly involve its
phosphorylation of the targeting subunit MYPT1, preventing MLCP
from removing activating phosphates on MLC20 [111].

This role is

considered critical in the sustained contraction seen in many
tissue types, and Rho kinase is seen to be expressed to a higher
level in those tissues that exhibit more tonic contractile
behavior [112]. However, studies also demonstrate that the procontractile effects of Rho Kinase may be mediated through
inhibition of NO synthesis, indirect phosphorylation of MLC20
through activation of Ca2+-independent ZIP kinase, and perhaps
direct phosphorylation of myosin [113-115].

ERK1/2
Extracellular signal-kinase types 1 and 2 (ERK1/2) are common
and prevalent participants in signaling cascades connected to
cellular activities of growth, differentiation, survival, and
metabolism.

A large portion of the downstream effects of ERK1/2

effect changes in gene expression in response to extracellular
signals or events [116].

ERK1/2 is also often involved in acute

effects or responses and its parent pathways are numerous and
well-described, and its targets of phosphorylation as varied.
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Effects on smooth muscle activity are easily connected to the
role of ERK1/2 in cell proliferation, as cytoskeletal
rearrangement is crucial to mitotic, differentiation, and motile
behaviors.

Phosphorylation of the putative contractile

regulators caldesmon and calponin by ERK1/2 enhance contraction
[54, 117].

ERK1/2 expression is heightened in models of

inflammatory disease of the gut, which often present with
hypercontractility [87, 118].

ERK activity is implicated in the

physiological contraction of gut and vascular smooth muscle [78,
119].

These effects of ERK1/2 can be mediated by

phosphorylation of participants in existing contractile pathways
incident upon MLCK or by direct phosphorylation of MLCK,
enhancing MLC20 phosphorylation [65, 66, 120].

CaMKII
Calcium-Calmodulin dependent kinase II (CaMKII) is a
serine/threonine kinase that is expressed widely in excitable
tissue. Upon binding with calcium-calmodulin (following a
transient increase in intracellular calcium), CaMKII
autophosphorylates at threonine 286 and can maintain its
activity after dissociating from calcium-calmodulin complexes
[37].

The kinase can modulate membrane channels and engage with

downstream kinases such as ERK1/2 [121-124].

CaMKII associates

with motor proteins in cell migration and hypertrophy, and has
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receptors and transport proteins of the sarcoplasmic reticulum
as targets [125-128].
In smooth muscle cells, inhibition of CaMKII can enhance
contraction, and this effect has been attributed to the effect
of CaMKII on MLCK [129]

Phosphorylation of MLCK by CaMKII

reduces the affinity of MLCK for calcium-calmodulin, decreasing
its phosphorylation of MLC20, and this phosphorylation has been
specifically blocked by inhibitors of CaMKII [130, 131].
However, other studies have indicated a possible link to CaMKII
activity and tone maintenance in vascular smooth muscle [132,
133].

These conflicting findings, along with the involvement of

CaMKII with proteins important in calcium handling (ryanodine
receptors, phospholamban) indicate the role of this enzyme in
calcium handling could be complex and not constant across
tissues with different calcium handling characteristics.

CaMKK/AMPK
Adenosine Monophosphate Activated Kinase (AMPK) is an
important regulator of cellular metabolism, involved in
adaptation of cellular processes to changes in metabolic level
(AMP:ATP ratio).

As AMP levels rise, enhanced AMPK activity

causes changes in glucose transport, lipid metabolism, and
mitochondrial activity [134-136].

Under normal conditions, AMPK

can be activated through receptor activation via calcium-
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calmodulin kinase kinase (CaMKK), with the beta isoform of CaMKK
being the most prevalent upstream mediator [137-139].
Inhibition of CaMKK is closely correlated with AMPK inhibition
and is the typical path of pharmacological manipulation [139141].
AMPK also associated with motor proteins.

AMPK interacts with

actin filaments of the cytoskeleton in osmotic stress models,
changing their affinity for other cytoskeletal proteins [142].
And studies have shown that MLCK is a substrate of AMPK, with
the phosphorylation of MLCK at a site close to the CaMKII
phosphorylation site, and resulting in a similar reduction in
affinity for calcium-calmodulin [143].

AMPK can phosphorylate

fragments of MLC20, but this is not thought to be part of the
normal activity of AMPK [144].

Putative Circular Muscle Model
Most gut smooth muscle studies are performed upon smooth
muscle cells or tissue from the circular muscle layer,
presumably because of its thickness and perceived dominant role
in gut motility.

Considering the literature regarding kinase

manipulations of MLCK/MLCP/MLC20, the following model is offered
(Figure 2).

Not all possible kinases or kinase targets were

mentioned and are beyond the scope of this study.

This model is

similar to many found in reviews and texts [39, 145-147].
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Figure 2. Putative Model for Circular Muscle Regulation
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Longitudinal Muscle
Longitudinal muscle in gut possesses many differences from the
circular muscle with which it works in opposition.

These

differences begin during development and lead to a muscle
phenotype that possesses a different receptor profile, membrane
lipid handling, and a mechanism of cytoplasmic calcium handling
more similar to striated cardiac muscle than any other form of
muscle, smooth or striated.

Development
The epithelium of the gut is derived from embryonic endoderm,
and the muscle from splanchnic mesoderm.

Neural precursor cells

of ectodermal origin begin to populate the gut almost
immediately, and their presence enables the mesenchyme to begin
to differentiate into what would become the circular muscle
layer [148].

There is debate on the origin of what will become

the longitudinal layer.

Some believe that longitudinal muscle

develop from circular muscle cells, others from a common
precursor that gives rise to both the ICCs and the longitudinal
muscle layer [149, 150].

Regardless, the development of the

longitudinal muscle is delayed relative to the circular, as this
is seen in both mouse model and human embryo [151].

ICCs are

often characterized by their expression of c-kit, a receptor
tyrosine kinase, as ICCs and mast cells are the only cells in
the gut that express c-kit.

Blockade of c-kit signaling in the
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gut abolishes the development of both the ICCs and the
longitudinal muscle, intimating that at the very least, ICC
signaling is necessary for longitudinal muscle development.

The

possibility the ICCs and longitudinal muscle cells come from the
same progenitor agrees with this finding [152].

Known

organogenetic proteins such as Shh, BMP, forkhead, and Wnt are
suspected to play roles in the radial patterning of the gut, it
seems that platelet derived growth factor (PDGF) may be the most
important [153].

Studies report that the cells destined to be

the longitudinal muscle layer express receptors for PDGF, which
is released by more internal parts of the gut.

This receptor

development could be caused by a gradient of these other
signaling proteins, but the combination of a substantive PDGF
receptor and appropriate ligand allows for longitudinal muscle
to differentiate from the c-kit expressing layer [154].

Receptors/Phosphoinositides
As stated earlier, the receptor population of circular muscle
cells and longitudinal muscle cells are different.

Longitudinal

muscle lacks receptors for opioids, somatostatin, and
neuropeptides Y2 and Y4 [27, 28, 42].

This variance in receptor

population coincides with a lesser degree of innervation that
longitudinal muscle possesses – the innervating neurons are
fewer in number, almost completely excitatory, and primarily
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cholinergic (secondary are the tachykinins).

Circular muscle is

innervated by excitatory and inhibitory neurons that offer a
greater variety of ligands to match the receptor variety.
Muscarinic receptors are common between the two muscle types,
and M3 activation in both muscle layers leads to activation of
PLC-1.

Other agonists and the M2 receptors can operate to

increase PLC-3 via Gi mechanism in both muscle types.

PLC

then turns upon membrane lipids as substrate for the generation
of second messengers.

Here, another variation is seen; in

circular muscle, the primary target of PLC is PIP2, and the
generated second messenger is IP3.

In longitudinal muscle, the

primary substrate is PIP and the generated second messenger IP2
[90, 93].
In circular muscle, the IP3 generated from PLC activity is
the ligand responsible for calcium liberation into the cytosol.
IP3 receptors on the sarcoplasmic reticulum bind to cytoplasmic
IP3, opening channels and increasing intracellular calcium,
enabling the contractile mechanism.

Longitudinal muscle

generates little IP3, and the sarcoplasmic reticula of
longitudinal muscle have very few IP3 receptors [50].

Yet,

contraction occurs in longitudinal muscle despite the signaling
differences.
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Calcium Handling
Longitudinal muscle does not generate IP3 nor does it have IP3
receptors on its sarcoplasmic reticular membrane.

A

fundamentally different mechanism is utilized to usher calcium
release into the cytosol.

The sarcoplasmic reticula of

longitudinal muscle possess ryanodine receptors, which are
insensitive to IP3.

These ryanodine receptors exist elsewhere in

the gut, even in circular muscle, but only in longitudinal
muscle is their contribution physiologically relevant and
necessary for contraction [155-157].

Sarcoplasmic reticula with

high populations of ryanodine receptors resemble a cardiac
muscle paradigm, and longitudinal muscle also shares with
cardiac muscle the mechanism by which the release of calcium
from the SR is regulated.
Studies with calcium channel blockers have shown that
contraction in circular muscle is not hindered by removal of
extracellular calcium or the block of sarcolemmal calcium
channels.

Eventually, contractions do decline in amplitude, but

this is a consequence of normal cellular extrusion of calcium.
Without entry of extracellular calcium, such stores will
eventually exhaust.

In longitudinal muscle, however, removal of

extracellular calcium or blockade of calcium entry diminishes
contractions immediately.

Just as in heart, the entry of

calcium into the cell is obligatory for the release of calcium
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from the sarcoplasmic reticulum in longitudinal muscle [158]
Such release is possible in circular muscle, but the necessary
concentration to trigger release is very high, and is primarily
seen in permeabilized cell preparations where such
concentrations can be realized [50].

Under physiological

conditions, calcium-induced calcium release is not seen in
circular muscle.
The mechanism that modulates calcium entry in longitudinal
muscle differs from its cardiac counterpart.

In heart, the

depolarization of the action potential is sufficient to gate
surface membrane calcium channels, allowing for the calcium
entry that triggers SR calcium release.

This is not necessary

for contraction in longitudinal smooth muscle, yet the membrane
must depolarize before the VDCCs can open.

As an excitable

tissue, it is reasonable that depolarization could spread
electrotonically from a distant locale, bringing the membrane to
threshold for the calcium channels, allowing calcium entry.

But

agonists can initiate contraction in isolated conditions with no
external depolarizing effort.
responsible.

A second messenger must be

The agent was discovered to be arachidonic acid

(AA), a polyunsaturated fatty acid that can be liberated from
membrane lipids by phospholipase A2 (PLA2) in the cytosol
(cytoplasmic PLA2, cPLA2) [159].

AA activates chloride

43

channels, causing the inward current that depolarizes the
membrane and gates the calcium channels.

Similar experiments in

circular muscle showed no connection between chloride channels,
AA, and calcium entry [160].

Further regulation is conveyed by

cyclic ADP-ribose (cADPR), an endogenous nucleotide known to
modulate calcium release from ryanodine-sensitive calcium
stores.

Circulating levels of cADPR can be increased through

receptor activation and stimulation of ADP-ribosyl cyclase,
enhancing SR ca efflux.

Circular muscle demonstrated no such

similar mechanism.

Rationale
Given the differences in development, receptor population,
lipid chemistry, and in particular, calcium handling, it is
hypothesized that the actions of the kinases known to modulate
MLC20 phosphorylation in circular muscle may have different
actions in longitudinal muscle.

Following the model in Figure

2, and using longitudinal muscle strips from rat colon, changes
in contractile behavior was measured in the presence and absence
of inhibitors for Rho Kinase (Y27632), ERK1/2 (PD98059), CaMKII
(KN-62), and CaMKK/AMPK (STO-609).
by carbachol (m2 and m3 activation).

Contraction was be elicited
Molecular techniques

illustrated direct effects of the kinases on MLCK.
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MATERIALS AND METHODS
Materials
Unless otherwise noted, all chemicals were obtained from
Sigma-Aldrich (St. Louis, MO).

Kinase Inhibitors Y27632 (Rho

kinase), PD98059 (ERK1/2), STO-609 (CaMKK/AMPK), and KN62
(CaMKII) were purchased from Calbiochem (La Jolla, CA).

15%

Tris-HCl Ready Gels and DC Protein Assay Kit were products of
Bio-Rad (Hercules, CA), Myelin Basic Protein was purchased from
Upstate Biotechnology (now Millipore, Billerica, MA) and [32

P]ATP from Perkin Elmer Life Sciences (Boston, MA).

Antibody

for MLCK and protein A/G agarose beads are products of Santa
Cruz Biotechnology (Santa Cruz, CA).
Sprague-Dawley Rats were purchased from Charles River
Laboratories (Wilmington, MA) and housed in the animal facility
of the Division of Animal Resources, Virginia Commonwealth
University.

All procedures followed guidelines of and were in

accordance with the Institutional Animal Care and Use Committee
of Virginia Commonwealth University.
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Animal Preparation
Rats were euthanized by CO2 asphyxiation under approved
protocols.

The colon was dissected out, emptied of contents and

placed in a warmed (37°C) oxygenated Krebs solution of the
following composition (in mM): 118 NaCl, 4.75 KCl, 1.19 KH2PO4,
1.2 MgSO4, 2.54 CaCl2, 25 NaHCO3, 11 mM glucose (pH 7.4).

2-3 cm

sections of colon were removed and threaded onto a glass rod,
where the longitudinal muscle/myenteric plexus (LM-MP) was
removed by radial abrasion with a lab wipe.

The resultant strip

of muscle was freed of excess fat and mesenteric attachments and
held in oxygenated Krebs buffer until use for tension recording
or molecular assay.

Strip Preparation
Strips destined for recordings of contractile behavior were
tied at both ends with surgical silk – on one end a simple loop
for attachment to a glass hook, the other end to a length of
silk tied to a brass ring.

The strip was then placed in a

vertical orientation with the loop secured to a glass hook and
the brass ring to a Model FT03C Force Transducer (Grass
Technologies, Quincy, MA).

An organ bath (Radnoti, Monrovia,

CA) was raised to submerge the strip in 5 mL of continuously
oxygenated and warmed Krebs solution.

Force recordings were

amplified by a 15A12 model amplifier (contained within a Model
15LT Amplifier System), relayed to a PVA-16 Polyview Adaptor
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Unit (A/D-D/A converter), and displayed/stored by a PC running
Polyview Version 1.3 (Grass Technologies, Quincy, MA).

Force

was recorded in grams per the software specifications.

All

analysis of data traces was performed within the Polyview
software itself, as exportation of usable raw data was limited
by software design.
Strips destined for molecular assay were treated as those
intended for recordings – time scales for inhibitor incubation
and agonist exposure were identical.

Following prescribed

incubation times, tissue strips were submerged in a bath of
Krebs with 1 M carbachol. After 60 seconds of immersion in
carbachol/Krebs (corresponding to a normal vigorous response
seen in strips), strips were flash frozen in liquid nitrogen and
placed into TPER (Tissue Protein Extraction Reagent, Pierce,
Rockford, IL) or lysis buffer with composition 50 mM Tris-HCl
(pH 7.5), 150 mM NaCl. 0.1% SDS, 0.5% sodium deoxycholate, 1%
NP-40, 10 mM sodium pyrophosphate.

Into either vehicle, a

protease/phosphatase cocktail (100 g/mL PMSF, 10 g/mL
leupeptin, 30 mM sodium fluoride and 3 mM sodium vanadate) was
added at a concentration of 2 L/mL.

Tissue was homogenized and

solubilized in the above solutions.

Following centrifugation at

20000 g for 15 min at 4°C, the protein concentration of the
supernatant was assessed with a DC protein assay kit.
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These

supernatant lysates were stored at -80°C until needed for
immunokinase assay.

Isometric Force Measurement
Force experiments were conducted in the following manner.
Following hanging of the strip and submersion in the organ bath,
strips were subjected to approximately 1 gram of pre-tension via
the mounting rack-and-pinion.

Strips were allowed to

equilibrate for no less than 30 minutes before experiments were
conducted and data collected.

Exposure to inhibitors, blockers,

and carbachol (sole agonist) occurred within the organ bath.
Concentrations were appropriate and in agreement with current
literature and are noted in the results.
Following an experiment, strip data were reviewed and analyzed
from within the Polyview software suite.

All experiments were

designed to compare treatment to control conditions.

Paired t-

tests were conducted in GraphPad (GraphPad Software, La Jolla,
CA), and significance assumed at P < 0.05. Often in summary,
treatment conditions were displayed as compared to control, but
significance relays to the raw data paired t-test.

Data Analysis
Contractile data was viewed from several perspectives as to
the effects of kinase inhibition: changes to basal tone upon
kinase inhibitor administration, peak contractile amplitude
48

following agonist exposure, and an area under the curve
measurement to quantify the contraction as viewed during the
first two minutes of the contraction in an effort to determine
differences in force development/decay. All numerical values are
offered as mean ± SEM.

Basal Tension
Basal tension was measured as the mean tension during a 3
minute period following at least 30 min of equilibration
(control conditions) or 10 min of inhibitor incubation (basal
recording obtained in interval proceeding carbachol
administration).

Such measurements were made in multiple strips

from multiple animals, and paired t-tests conducted to
demonstrate a significantly appreciable effect.

Peak Contraction
Peak contraction (amplitude) was defined to be the greatest
amplitude of tone above basal during the two minute period
following agonist administration.

This two minute period is

taken to begin when tone appreciably elevates from basal value.
Differing geometries of the shape of the contraction waveform
allows for this peak measurement to occur at varying time
indices following carbachol administration.

An example of such

a measurement (utilizing a constructed model curve) is displayed
in Figure 3.
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Figure 3. Peak Amplitude Measurement.
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Contraction at 1 min and 2 min post exposure
In strips that developed an early peak that subsided quickly,
the amplitude of the contraction above basal was also recorded
at 1 minute and 2 minutes following the initial increase in tone
due to agonist administration (the beginning of the studied
interval). An example of such measurements (utilizing
constructed model curves) is displayed in Figures 4 and 5.

AUC for first minute and first two minutes of exposure
The area underneath a curve representing force versus time has
no physical definition in an isometric contraction.

Energy

expenditure cannot be quantified without a displacement.

But

along with the values of the contraction at 1 min and 2 min as
percentage of peak, these quantities do speak to the development
and maintenance of the tension, and do help describe the decay
of the same.

This is a typical method used to describe

contraction curves in muscle strips.

Examples of these

measurements: AUC 0-1 min, AUC 1-2 min, and AUC 0-2 min
(utilizing constructed model curves) are offered in Figures 6-8.
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Figure 4. Contraction at t = 1 minute.
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Figure 5. Contraction at t = 2 minutes.
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Figure 6. Area under the curve, 0-1 minute.
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Figure 7. Area under the curve, 1-2 minutes.

59

60

Figure 8. Area under the curve, 0-2 minutes.
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Kinase Assay
Activities of MLCK activity were measured by an immunokinase
assay as performed in earlier studies from the lab [85, 88, 161,
162].

100 g of protein was transferred from the supernatant of

prepared tissue sample to a designated tube and 1 μg of MLCK
goat antibody was added.
2 hours.

At 4°C, this mixture was incubated for

Protein A/G agarose beads were added to each sample,

and the mixture again incubated at 4°C overnight.

Following

centrifugation, supernatants were withdrawn and the
beads/protein washed with lysis buffer three times.
The bead/protein pellets were resuspended in kinase buffer
with composition (in mM): 100 tris-HCl, 1000 KCl, 50 MgCl2, 10
EDTA, and 1 DTT.

Twenty microliters of this mixture were added

to a reaction mixture of (in mM): 100 tris-HCl, 1 KCl, 50 MgCl2,
1 DTT, 1 ATP, and 10 Ci of [-32P]ATP (3000 Ci/mol) with 5 g
myelin basic protein as kinase target substrate.
was incubated for 15 min at 37°C.

This mixture

Twenty microliters of this

mixture (and the accompanying myelin basic protein
phosphorylated with -32P) was absorbed onto phosphocellulose
filter paper disks, and free radioactivity washed away by
repeated immersion in 75 mM H3PO4.

Radioactivity was then

measured by liquid scintillation, and values expressed as
counts/minute per microgram of protein.
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RESULTS
Sample Traces
Sample traces are offered to demonstrate the variety of
contraction waveforms.

Most contractions studied (~75%) possess

a waveform similar to the top panel of Figure 9 – a sharp rise
in developed tension, followed by a decrease to a sustained
level within 60-90 seconds.

Other contractions (~20%) may show

a rise in tension without appreciable decay, maintaining an
elevated tone, as in the bottom panel of Figure 9.

Contractions

that demonstrated little decline following an early peak were
not utilized in measurements that attempted to quantify the
decay in tension (t = 1 min, t = 2 min studies).
In addition, contractions may exhibit phasic activity
superimposed upon the described waveforms.
waveforms in displayed in Figure 10.

An example of such a

For waveforms with

prominent phasic components, contraction values at 1 min and 2
min were interpolated values.

Area under the curve values were

utilized as recorded, unless phasicity was extreme enough to
take the minima of contractions to values below the initial
baseline tension.

Polyview software would treat such as

negative areas under the curve and complicate the analysis.
Such tracings were not utilized for AUC data.
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Figure 9. Sample traces from main Polyview screen.
Top Panel: Trace indicative of early peak tension development
and substantial decay to sustained level.

Trace line enhanced

for ease of viewing
Bottom Panel: Trace indicative of little decay following peak
tension.

Trace line enhanced for ease of viewing.
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Figure 10. Sample partial trace from Zoom screen of Polyview
Software suite.
Trace indicative of strips that exhibit phasic activity
superimposed upon standard decay.

Zoom feature of Polyview

automatically filters and smoothes resultant data.
are performed on original raw data.
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Calculations
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Control Behavior of Strips due to carbachol
Strips were exposed to carbachol (CCh) at concentrations of 10
nM, 1 M, and 100 M.

10 nM elicited contraction in strips

approximately 50% of the time, and data from these responsive
strips were utilized. 1 M CCh consistently produced robust
responses, and 100 M CCh reliably produced a maximal response.
These doses are consistent with similar studies conducted using
strips [40, 163].
Circular muscle strips were not viable preparations in this
study.

Although circular muscle strips can be prepared from

human tissue reliably, in rat it is apparent that the
longitudinal muscle layer provides needed integrity to the
muscle strip – in its absence, circular muscle tears easily
(along its physiological orientation) when subjected to tension.
Similar difficulties have been noted in the literature [163,
164].

Contraction Dose response
The grand mean of control responses by carbachol dose are
displayed in Figure 11.

Contractile responses were 0.51 ± 0.06

grams at 10 nM CCh (n=40), 1.00 ± 0.12 grams at 1 M CCh (n=50)
and 1.80 ± 0.18 grams at 100 M CCh (n=54).

These force

measurements are not normalized by mass and demonstrate the
variability among strips used in the experiments.
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However, all

strips serve as individual controls for the experimental
treatments, and all statistical tests are suitably conducted on
repeated measurements.

Contraction at 1 and 2 min post exposure
Measured tension at time points 1 minute and 2 minutes
following the initial tension increase were compared to peak
values and expressed as a percentage

At t=1 minute, the

percentages of peak tension were 74.28% ± 4.32% for 10 nM CCh
(n=16), 74.97% ± 3.09% for 1 M CCh (n=23), and 64.69% ± 4.23%
for 100 M CCh (n=29).

At t=2 minutes, the percentage values

respectively were 65.56% ± 6.67% (n=15), 62.85% ± 4.96% (n=26),
and 47.87% ± 4.13% (n=29).

These data are summarized in Figure

12.

Area under the curve for control contractions
Areas under the response curves were calculated for the first
minute (AUC 0-1 min), second minute (AUC 1-2 min), and first two
minutes (AUC 0-2 min).

For AUC 0-1 min, values were 16.79 ±

2.83 gram-seconds at 10 nM CCh (n=35), 38.86 ± 5.09 gram-seconds
at 1 μM CCh (n=42), and 77.25 ± 8.65 gram-seconds at 100 μM CCh
(n=46).

For AUC 1-2 min, values were 22.85 ± 4.01 gram-seconds

at 10 nM CCh (n=35), 46.89 ± 7.42 gram-seconds at 1 μM CCh
(n=38), and 53.00 ± 7.09 gram-seconds at 100 μM CCh (n=44).

For

AUC 0-2 min, values were 34.44 ± 5.84 gram-seconds at 10 nM CCh
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(n=34), 83.62 ± 11.35 gram-seconds at 1 μM CCh (n=42), and
133.25 ± 14.67 gram-seconds at 100 μM CCh (n=45).
this data is displayed in Figure 13.
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A summary of

Figure 11. Control contractile response to carbachol.
Grand mean of all responses.

(n=40 for 10 nM CCh, n=50

for 1 μM CCh, and n=54 for 100 μM CCh).
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Contraction (g)
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10-4

Figure 12. Percentage of Peak Amplitude remaining at t = 1 min
and t = 2 min for control responses.
Sample sizes for t=1 minute: for 10 nM CCh (n=16), for 1 M
CCh (n=23), and for 100 M CCh (n=29).

At t=2 minutes,

respective sample sizes: n=15, n=26, and n=29.

74

Percent of Peak amplitude
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Figure 13. AUC 0-1 min, AUC 1-2 min, and AUC 0-2 min data for
control responses.
Sample sizes range from 32 to 45 among the three metrics.
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Repeated Measurements
Repeated measurements of peak amplitude and area under the
curve were conducted on strips in absence of kinase inhibition.
This was to ensure that any change in contractile behavior is
not an artifact of de-sensitization to agonist or strip fatigue.
Strips were exposed to 1 μM CCh, contractions measured.
Following a wash, strips were incubated for 15 min in Krebs
solution, and dosed again with 1 μM CCh, to mimic the incubation
period with kinase inhibitors.
of initial contraction/AUC.

Data are expressed as percentage

Paired t-tests were conducted to

assess significance between initial and repeated measurements.

Peak Amplitude/Area under the curve repeated measurements
Following a 15 min incubation after initial contraction, peak
recorded tension in strips was 98.29% ± 3.99% of the initial
recording (n=13, 5 animals).
14.

Summary data displayed in Figure

Following a 15 min incubation period, strips exhibited

contractions with AUC 0-1 min and AUC 0-2 min that were 99.00% ±
2.148% (n=13, 5 animals) and 102.1% ± 1.881% (n=13, 5 animals)
respectively.

No significant differences were seen with

repeated measures (all P > 0.05).
Figure 15.
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These data are summarized in

Figure 14. Peak Contractions of Repeated Measurements.
Repeated peak recorded tension in strips was 98.29% ± 3.99% of
the initial recording (n=13, 5 animals).
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No significance noted.
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Figure 15. AUC 0-1 min and AUC 0-2 min values for repeated
measurements.
Repeated AUC 0-1 min and AUC 0-2 min values were 99.00% ±
2.148% (n=13, 5 animals) and 102.1% ± 1.881% (n=13, 5 animals)
of the original recordings.

No significance noted.
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Effects of Muscarinic Antagonism
Contraction in longitudinal muscle is mediated primarily by m3
receptors.

Smooth muscle cells expressed a greater number of m2

receptors, but these receptors are not definitively involved in
acute contractile behavior.

Strips were subjected to 1 μM CCh

before and after incubation with methoctramine (m2 receptor
antagonist) and 4-DAMP (m3 receptor antagonist).

Incubation

with 1 μM methoctramine caused no significant changes to peak
contraction, AUC 0-1 min, or AUC 0-2 min induced by 1 μM
carbachol (all P > 0.05, n=7 from 4 animals).

Incubation with 1

μM 4-DAMP prevented all responses to 1 μM carbachol (n=6).
Results are summarized in Figure 16.
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Figure 16. Effect of muscarinic antagonists on CCh-induced
contraction.
1 μM methoctramine showed no significant effect upon 1 μM CCh
induced contraction.

1 μM 4-DAMP completed blocked all

contraction induced by CCh. n=7 from 4 animals.
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Effects of Neural Inhibition (TTX)
Repeated measurements were conducted in the presence of 1 μM
tetrodotoxin (TTX), a Na+ channel blocker, in order to
investigate any neural influence on contractile behavior.

Peak

contractions, contractions at 1 minute and 2 minutes, and area
under the curve data were collected after 15 min incubation with
TTX and compared to control contractions.

Peak Contraction due to carbachol
The peak contraction elicited by all concentrations of CCh was
not significantly affected by TTX administration.

Viewed as

percentage of control contraction, TTX exposure led to
contractions 102.8% ± 5.98% of the control value at 1 μM CCh
(n=7), 113.2% ± 8.6% at 10 μM CCh (n=7), and 110.5% ± 9.02% at
100 μM CCh (n=7).

Again, although mean contractions were

increased with TTX incubation, the values only approached
significance (all P-Values > 0.05).

Summary data for Peak

contraction in the presence of TTX is offered in Figure 17.

Contraction at 1 min and 2 min minutes post exposure
Contraction at 1 min and 2 minute was recorded under control
conditions and after incubation with TTX.

Raw values and

percent of peak contraction are offered.

As with the peak

contraction, 1 μM TTX cause no significant change in the
amplitude of contraction at t = 1 minute and t = 2 minutes.
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A t

= 1 minute, control versus TTX had amplitudes (in grams) of 1.85
± 0.13 versus 1.78 ± 0.12 for 1 μM CCh (n=5), 2.14 ± 0.20 versus
2.04 ± 0.16 grams for 10 μM CCh (n=5), and 2.39 ± 0.19 versus
2.10 ± 0.14 grams for 100 μM CCh (n=5).

At t = 2 minutes,

control versus TTX had amplitudes (in grams) of 1.67 ± 0.05
versus 1.49 ± 0.07 for 1 μM CCh (n=5), 1.79 ± 0.21 versus 1.62 ±
0.07 grams for 10 μM CCh (n=5), and 1.76 ± 0.08 versus 1.80 ±
0.11 grams for 100 μM CCh (n=5).

These data and percent

summaries are included in Figure 18.

Area under curve for first two minutes
Similarly, 1 μM TTX has no significant effect upon the area
under the curve for the first minute and first two minutes of
contractions elicited by CCh at all tested concentrations. For
AUC 0-1 min, control versus TTX had values (in gram-seconds) of
63.25 ± 10.64 for versus 60.42 ± 9.23 for 1 μM CCh (n=5), 104.3
± 13.28 versus 121.2 ± 18.82 grams for 10 μM CCh (n=5), and
112.9 ± 13.27 versus 128.5 ± 27.21 grams for 100 μM CCh (n=5).
For AUC 0-2 min, control versus TTX had values (in gramseconds) of 106.5 ± 18.73 for versus 98.44 ± 12.09 for 1 μM CCh
(n=5), 149.3 ± 23.02 versus 183.2 ± 31.53 grams for 10 μM CCh
(n=5), and 192.5 ± 32.68 versus 220.0 ± 38.89 grams for 100 μM
CCh (n=5).

These data and percent summaries are included in

Figure 19.

87

Figure 17. Peak Contraction Data in the presence of TTX versus
control.
102.8% ± 5.98% of control at 1 μM CCh (n=7), 113.2% ± 8.6% at 10 μM
CCh (n=7), and 110.5% ± 9.02% at 100 μM CCh (n=7).
determined.
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No significance
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Figure 18. Contractions at 1 min and 2 min in the presence of TTX
versus control.
No significant difference in contractions at 1 min and 2 min post
carbachol in TTX-incubated group versus control group.
at least three animals.
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n = 5 from
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Figure 19. AUC 0-1 min and AUC 0-2 min values in the presence
of TTX versus control.
No significant differences noted in AUC values between TTX
group and carbachol group.

n = 5 minimum from at least 3

animals.
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Effects of Rho Kinase Inhibition (Y27632)
Rho kinase is known to affect the phosphatase leg of
contractile regulation through its direct phosphorylation of
MYPT1 and its indirect phosphorylation of CPI-17 via PLD-DAGPKC.

Incubation of strips for 15 minutes in 10 μM Y27632 (a

powerful Rho Kinase inhibitor) allows for comparison of Rhokinase inhibited contraction to control conditions.

Rho kinase

inhibition was viewed from the contractile perspectives of basal
tone regulation, peak contraction, contraction at one and two
minutes post CCh exposure, and area under the curve values.

The

possible effect of Rho kinase inhibition on MLCK activity was
studied via molecular methods.

Basal Activity
Rho kinase inhibition led to a significant decrease in basal
tone after 10 minutes of incubation.

In studied strips (n=15),

administration of Y27632 (Rho kinase inhibition) resulted in a
change of basal tone from 0.82 ± 0.07 grams to 0.73 ± 0.06
grams.

A conducted paired t-test returned P < 0.01; the

inhibition of Rho kinase reduces basal tone.
and displayed in Figure 20.
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Data summarized

Figure 20. Effect of Rho Kinase inhibition on basal tone.
Administration of 10 μM Y27632 for 10 min resulted in a
reduction of basal tone from 0.82 ± 0.07 grams to 0.73 ± 0.06
grams (* indicates P < 0.05, n=12).
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Peak Contraction due to carbachol
Rho kinase inhibition (via Y27632 incubation) significantly
reduced contraction for carbachol concentrations of 1 μM and 100
μM.

Control peak contraction values (in grams) versus

contractions following Y27632 incubation are 0.80 ± 0.30 versus
0.30 ± 0.08 (P > 0.05, n=4) at 10 nM CCh; 1.13 ± 0.28 versus
0.71 ± 0.19 (P < 0.01, n=15) for 1 μM CCh; and 2.17 ± 0.38
versus 1.21 ± 0.23 (P < 0.05, n=16) at 100 μM CCh.

Summary data

are displayed in Figure 21.

Contraction at 1 min and 2 min minutes post exposure
Rho kinase inhibition reduced the contraction at both 1 min
and 2 min post CCh exposure for all concentrations of CCh.

With

10 nM CCh, 1 minute control values (in grams) versus Y27632
incubation were 1.34 ± 0.17 versus 0.72 ± 0.15 (P < 0.05), 2
minute values were 1.11 ± 0.06 for control versus 0.64 ± 0.08
for Y27632 incubation (P < 0.01, both n=3); for 1 μM CCh, 1
minute control values (in grams) were 1.76 ± 0.31 versus 0.83 ±
0.11 (P < 0.05), 2 minute values were 1.45 ± 0.22 for control
versus 0.77 ± 0.10 grams for Y27632 incubation (P < 0.05, both
n=6); for 100 μM CCh, 1 minute control values (in grams) versus
Y27632 incubation were 1.70 ± 0.21 versus 1.14 ± 0.18 (P <
0.01), 2 minute control values were 1.48 ± 0.16 versus 1.08 ±
0.15 for Y27632 incubation (P < 0.01, both n=9).
summarized in Figure 22.
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Data

Figure 21. Effect of Rho Kinase Inhibition on Peak Contraction.
Top Panel: Rho Kinase inhibition significantly reduced peak
contraction elicited by 1 μM CCh (1.13 ± 0.28 versus 0.71 ± 0.19
grams, n=15) and by 100 μM CCh (2.17 ± 0.38 versus 1.21 ± 0.23
grams, n=16). (* = P < 0.05)
Bottom Panel: Summary data expressed as percentage of control.
(* = P < 0.05)

98

99

Figure 22. Effect of Rho Kinase Inhibition at 1 min and 2 min
post CCh exposure.
Top Panel: Tone was reduced at t = 1 min and t = 2 min with
Rho kinase inhibition. Sample Sizes range from 3 to 9. (* = P <
0.05)
Bottom Panel: t = 1 min and t = 2 min data expressed by
percentage of control.

100

101

Area under curve for first two minutes
Rho Kinase inhibition caused a significant decrease in the
area under the curve metric in the first (AUC 0-1), second (AUC
1-2), and first two minutes (AUC 0-2) for contractions elicited
by 1 μM and 100 μM CCh.

AUC data for 10 nM CCh contractions

were not significantly reduced.

For AUC 0-1 min, control versus

Y27632 incubation values (in gram-seconds): for 100 nM CCh,
13.08 ± 8.85 versus 3.608 ± 2.00 (P > 0.05, n=5); for 1 μM CCh,
46.05 ± 9.86 versus 15.02 ± 3.56 (P < 0.01, n=13); for 100 μM
CCh, 85.81 ± 15.41 versus 42.86 ± 7.68 (P < 0.01, n=16).

For

AUC 1-2 min, control versus Y27632 incubation values (in gramseconds): for 100 nM CCh, 14.93 ± 9.17 versus 3.917 ± 1.87 (P >
0.05, n=3); for 1 μM CCh, 64.13 ± 15.90 versus 21.83 ± 5.48 (P <
0.01, n=13); for 100 μM CCh, 56.82 ± 12.61 versus 31.06 ± 6.07
(P < 0.05, n=15).

For AUC 0-2 min, control versus Y27632

incubation values (in gram-seconds): for 100 nM CCh, 35.54 ±
24.26 versus 9.503 ± 5.223 (P > 0.05, n=3); for 1 μM CCh, 120.8
± 25.15 versus 39.90 ± 9.417 (P < 0.01, n=10); for 100 μM CCh,
142.7 ± 26.03 versus 74.87 ± 13.31 (P < 0.01, n=15).
data for AUC values is presented in Figure 23.
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Summary

Figure 23. Effect of Rho kinase inhibition on AUC values.
Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100
μM. Sample sizes range from 5 to 16. (* indicates P < 0.05)
Bottom Panel: Data expressed as percentage of control.
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MLCK activity
The effect of Rho kinase inhibition on MLCK activity was
measured using immunokinase assay.

MLCK activity was measured

in longitudinal muscle-myenteric plexus (LM-MP) strip
homogenates of four groups: control, following 10 min incubation
of 10 μM Y27632, 1 min post 1 μM CCh exposure, and 1 min post 1
μM CCh exposure following 10 min incubation with 10 μM Y27632.
1 μM CCh increased MLCK activity to 167% ± 21% of control
activity (P < 0.05 versus control, n = 12).

Incubation for 10

min with Y27632 reduced CCh-induced activity to 122% ± 11% of
control activity (P < 0.05 versus control, n = 8).

Incubation

of Y27632 alone did not differ MLCK from control (n = 12 for
control, n = 4 for Y27632 alone).

CCh-induced activity was not

significantly varied between strips with and without Rho Kinase
inhibition (n = 12 for CCh, n = 8 for CCh with Y27632
incubation).

Results are shown in Figure 24.
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Figure 24.

Effect of Rho Kinase Inhibition on CCh-evoked MLCK

activity.
1 μM CCh-induced MLCK activities with and without Rho Kinase
inhibition are presented.

Values expressed as percentage ± SEM

of control MLCK activity.

Control, n = 12.

CCh-induced

activity is 167% ± 21% of control (P < 0.05, n = 12).

CCh

activity in the presence of 10 μM Y27632 reduces CCh-induced
activity to 122% ± 11% of control (P < 0.05, n = 8).
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Effects of ERK1/2 Inhibition (PD98059)
Incubation of strips for 15 minutes in 10 μM PD98059 (an
ERK1/2 inhibitor) allows for comparison of ERK1/2 inhibited
contraction to control conditions.

ERK1/2 inhibition was viewed

from the contractile perspectives of basal tone regulation, peak
contraction, contraction at one and two minutes post CCh
exposure, and area under the curve values.

Possible additive

effects of ERK1/2 inhibition (postulated to work as kinase
regulator) and Rho Kinase inhibition (known phosphatase
regulator) are studied.

The effect of ERK1/2 inhibition on MLCK

activity was studied via molecular methods.

Basal Activity
ERK1/2 inhibition led to no significant change in basal tone
after 10 minutes of incubation.

In studied strips (n=12),

administration of PD98059 (ERK1/2 inhibition) resulted in a
change of basal tone from 0.79 ± 0.06 grams to 0.81 ± 0.05
grams.

A conducted paired t-test returned P > 0.05; the

inhibition of ERK1/2 does not affect basal tone.

Data

summarized and displayed in Figure 25.

Peak Contraction due to carbachol
ERK1/2 inhibition (via PD98059 incubation) significantly
reduced contraction for all carbachol concentrations.

Control

peak contraction values (in grams) versus contractions following
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PD98059 incubation are 0.47 ± 0.13 versus 0.28 ± 0.08 (P < 0.05,
n=6) at 10 nM CCh; 0.86 ± 0.13 versus 0.49 ± 0.09 (P < 0.01,
n=9) for 1 μM CCh; and 2.06 ± 0.38 versus 1.40 ± 0.32 (P <
0.001, n=9) for 100 μM CCh.

Summary data are displayed in

Figure 26.

Contraction at 1 min and 2 min minutes post exposure
ERK1/2 inhibition reduced the contraction at both 1 min and 2
min post CCh exposure for all concentrations of CCh.

With 10 nM

CCh, 1 minute control values (in grams) versus PD98059
incubation were 1.07 ± 0.15 versus 0.90 ± 0.14 (P < 0.01), 2
minute values were 0.88 ± 0.09 for control versus 0.77 ± 0.09
for PD98059 incubation (P < 0.01, both n=4); for 1 μM CCh, 1
minute control values (in grams) were 1.56 ± 0.12 versus 1.13 ±
0.08 (P < 0.01), 2 minute values were 1.36 ± 0.14 for control
versus 1.01 ± 0.05 grams for PD98059 incubation (P < 0.01, both
n=4); for 100 μM CCh, 1 minute control values (in grams) versus
PD98059 incubation were 1.86 ± 0.13 versus 1.45 ± 0.11 (P <
0.01), 2 minute control values were 1.54 ± 0.12 versus 1.15 ±
0.09 for PD98059 incubation (P < 0.01, both n=4).

Data

summarized in Figure 27.

Area under curve for first two minutes
ERK1/2 inhibition caused a significant decrease in the area
under the curve metric in the first (AUC 0-1), second (AUC 1-2),
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and first two minutes (AUC 0-2) for contractions elicited by 1
μM and 100 μM CCh.

AUC values for 10 nM CCh contractions were

significantly reduced only for the AUC 0-1 min segment.

For AUC

0-1 min, control versus PD98059 incubation values (in gramseconds): for 10 nM CCh, 18.92 ± 4.19 versus 11.07 ± 2.25 (P >
0.05, n=4); for 1 μM CCh, 42.06 ± 8.11 versus 22.18 ± 4.70 (P <
0.05, n=6); for 100 μM CCh, 83.18 ± 14.69 versus 54.59 ± 10.46
(P < 0.01, n=9).

For AUC 1-2 min, control versus PD98059

incubation values (in gram-seconds): for 10 nM CCh, 19.27 ± 4.56
versus 11.73 ± 2.78 (P < 0.05, n=4); for 1 μM CCh, 48.45 ± 10.45
versus 24.58 ± 3.25 (P < 0.05, n=7); for 100 μM CCh, 58.07 ±
10.41 versus 33.06 ± 7.19 (P < 0.01, n=9).

For AUC 0-2 min,

control versus PD98059 incubation values (in gram-seconds): for
10 nM CCh, 31.22 ± 9.69 versus 18.78 ± 5.57 (P > 0.05, n=7); for
1 μM CCh, 87.82 ± 17.61 versus 47.16 ± 6.56 (P < 0.01, n=7); for
100 μM CCh, 141.3 ± 23.86 versus 87.66 ± 16.69 (P < 0.01, n=9).
Summary data for AUC values is presented in Figure 28.
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Figure 25. Effect of ERK1/2 Inhibition on Basal Tone.
Administration of 10 μM PD98059 for 10 min resulted in no
significant reduction of basal tone (0.79 ± 0.06 grams versus
0.81 ± 0.05 grams, n=12).
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Figure 26. Effect of ERK 1/2 Inhibition on Peak Contraction.
Top Panel: Summary data expressed as percentage of control.
(* = P < 0.05)
Bottom Panel: ERK1/2 inhibition significantly reduced peak
contraction elicited by 10 nM CCh (0.47 ± 0.13 versus 0.28 ±
0.08, n=6), 1 μM CCh (0.86 ± 0.13 versus 0.49 ± 0.09 grams, n=9)
and by 100 μM CCh (2.06 ± 0.38 versus 1.40 ± 0.32 grams, n=9. (*
= P < 0.05)
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Figure 27. Effect of ERK 1/2 Inhibition on contraction at 1
min and 2 min post CCh exposure.
Top Panel: Tone was reduced at t = 1 min and t = 2 min with
ERK1/2 inhibition. n=4 for all sets. (* = P < 0.05)
Bottom Panel: t = 1 min and t = 2 min data expressed by
percentage of control.
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Figure 28. Effects of ERK1/2 Inhibition on AUC Values.
Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100
μM. Sample sizes range from 4 to 9. (* indicates P < 0.05)
Bottom Panel: Data expressed as percentage of control.
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Combination Effects with Rho Kinase inhibition
ERK1/2 inhibitor PD98059 was used in concert with Rho Kinase
inhibitor Y27632 to observe any additive effect.

In 6 strips so

tested, both 10 μM PD98059 alone and 10 μM PD98059 with 10 μM
Y27632 significantly inhibited contraction elicited by 1 μM CCh:
1.17 ± 0.19 grams for Control, 0.96 ± 0.14 grams for PD98059
alone (P < 0.05), 0.85 ± 0.13 grams for both inhibitors (P <
0.05).

However, there was no significant difference between the

single inhibitor PD98059 and the use of both inhibitors
simultaneously.

These results are displayed in Figure 29.
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Figure 29. Combination effects of ERK1/2 and Rho Kinase
Inhibition on Amplitude.
10 μM PD98059 alone and with 10 μM Y27632 (Rho kinase
inhibition) significantly reduced peak contraction as compared
to control.

Additive effects were not observed.

indicates P < 0.05)
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(n=6, *
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MLCK activity
The effect of ERK1/2 inhibition on MLCK activity was measured
using immunokinase assay.

MLCK activity was measured in

longitudinal muscle-myenteric plexus (LM-MP) strip homogenates
of four groups: control, following 10 min incubation of 10 μM
PD98059, 1 min post 1 μM CCh exposure, and 1 min post 1 μM CCh
exposure following 10 min incubation with 10 μM PD98059.

1 μM

CCh increased MLCK activity to 167% ± 21% of control activity (P
< 0.05 versus control, n = 12).

Incubation for 10 min with

PD98059 lead to CCh-induced activity that was 119% ± 21% of
control activity (P > 0.05, n = 8).

Incubation of PD98059 alone

did not differ MLCK from control (n = 12 for control, n = 4 for
PD98059 alone).

CCh-induced activity was not significantly

varied between strips with and without ERK1/2 inhibition (n = 12
for CCh, n = 8 for CCh with ERK1/2 incubation).
shown in Figure 30.
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Results are

Figure 30. Effect of ERK1/2 Inhibition on CCh-evoked MLCK
activity.
1 μM CCh-induced MLCK activities with and without ERK1/2
inhibition are presented.

Values expressed as percentage ± SEM

of control MLCK activity.

Control, n = 12.

CCh-induced

activity is 167% ± 21% of control (P < 0.05, n = 12).

CCh-

induced activity in the presence of 10 μM PD98059 was 122% ± 11%
of control (P > 0.05, n = 8).
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Effects of CaMKK/AMPK Inhibition (STO-609)
Incubation of strips for 15 minutes in 10 μM STO-609 (a
CaMKK/AMPK inhibitor) allows for comparison of CaMKK/AMPK
inhibited contractions to control conditions.

CaMKK/AMPK

inhibition was viewed from the contractile perspective in basal
tone regulation, peak contraction, contraction at one and two
minutes post CCh exposure, and area under the curve values.

The

effect of CaMKK/AMPK inhibition on MLCK activity was studied via
molecular methods.

Basal Activity
CaMKK/AMPK inhibition led to no significant change in basal
tone after 10 minutes of incubation.

In strips so studied

(n=7), administration of STO-609 (CaMKK/AMPK inhibition)
resulted in a change of basal tone from 0.76 ± 0.10 grams to
0.74 ± 0.10 grams.

A conducted paired t-test returned P > 0.05;

the inhibition of CaMKK/AMPK has no effect upon basal tone.
Data summarized and displayed in Figure 31.
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Peak Contraction due to carbachol
CaMKK/AMPK inhibition (via STO-609 incubation) significantly
reduced contraction for carbachol concentrations of 1 μM and 100
μM.

Control peak contraction values (in grams) versus

contractions following STO-609 incubation are 0.51 ± 0.16 versus
0.32 ± 0.14 (P > 0.05, n=6) at 10 nM CCh; 1.31 ± 0.20 versus
0.81 ± 0.15 (P < 0.01, n=23) for 1 μM CCh; and 1.96 ± 0.37
versus 1.22 ± 0.20 (P < 0.05, n=16) for 100 μM CCh.

Summary

data are displayed in Figure 32.

Contraction at 1 min and 2 min minutes post exposure
CaMKK/AMPK inhibition significant reduced the contraction at
both 1 min and 2 min post CCh exposure for CCh concentrations of
10 nM and 1 μM.

With 10 nM CCh, 1 minute control values (in

grams) versus STO-609 incubation were 1.18 ± 0.16 versus 0.86 ±
0.09 (P < 0.05), 2 minute values were 1.15 ± 0.17 for control
versus 0.86 ± 0.10 for STO-609 incubation (P < 0.05, both n=4);
for 1 μM CCh, 1 minute control values (in grams) were 1.54 ±
0.19 versus 1.29 ± 0.18 (P < 0.01), 2 minute values were 1.37 ±
0.18 for control versus 1.17 ± 0.16 grams for STO-609 incubation
(P < 0.05, both n=16); for 100 μM CCh, 1 minute control values
(in grams) versus STO-609 incubation were 1.63 ± 0.23 versus
1.33 ± 0.29 (P > 0.05), 2 minute control values were 1.31 ± 0.25
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versus 0.98 ± 0.19 for STO-609 incubation (P > 0.06, both n=6).
Data summarized in Figure 33.

Area under curve for first two minutes
CaMKK/AMPK inhibition caused a significant decrease in the
area under the curve metric in the first (AUC 0-1), second (AUC
1-2), and first two minutes (AUC 0-2) for all CCh contractions.
AUC values for 10 nM CCh contractions were not significantly
reduced.

For AUC 0-1 min, control versus STO-609 incubation

values (in gram-seconds): for 10 nM CCh, 28.99 ± 3.03 versus
15.23 ± 1.59 (P < 0.01, n=5); for 1 μM CCh, 52.88 ± 10.26 versus
38.36 ± 7.19 (P < 0.01, n=13); for 100 μM CCh, 91.68 ± 20.41
versus 48.86 ± 8.78 (P < 0.05, n=9).

For AUC 1-2 min, control

versus STO-609 incubation values (in gram-seconds): for 10 nM
CCh, 33.5 ± 5.57 versus 22.39 ± 3.58 (P < 0.05, n=4); for 1 μM
CCh, 52.06 ± 10.40 versus 35.00 ± 5.54 (P < 0.05, n=17); for 100
μM CCh, 56.69 ± 13.85 versus 36.90 ± 6.71 (P < 0.05, n=9).

For

AUC 0-2 min, control versus STO-609 incubation values (in gramseconds): for 10 nM CCh, 62.64 ± 5.40 versus 40.46 ± 4.61 (P <
0.01, n=7); for 1 μM CCh, 85.42 ± 13.77 versus 54.67 ± 7.92 (P <
0.01, n=15); for 100 μM CCh, 114.6 ± 16.23 versus 81.29 ± 13.01
(P < 0.01, n=9).

Summary data for AUC values is presented in

Figure 34.
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Figure 31. Effect of CaMKK/AMPK inhibition on basal tone.
Administration of 10 μM STO-609 for 10 min resulted in no
significant reduction of basal tone (0.76 ± 0.10 grams versus
0.71 ± 0.10 grams, n=7).
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Figure 32. Effect of CaMKK/AMPK inhibtion on peak contraction.
Top Panel: CaMKK/AMPK inhibition significantly reduced peak
contraction elicited by 1 μM CCh (1.31 ± 0.20 versus 0.81 ± 0.15
grams, n=9) and by 100 μM CCh (1.96 ± 0.37 versus 1.22 ± 0.20
grams, n=9. (* = P < 0.05)
Bottom Panel: Summary data expressed as percentage of control.
(* = P < 0.05)
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Figure 33. Effect of CaMKK/AMPK inhibition on contractions at
1 min and 2 min post CCh exposure.
Top Panel: Tone was reduced at t = 1 min and t = 2 min with
Rho kinase inhibition. Sample Sizes range from 4 to 16. (* = P <
0.05)
Bottom Panel: t = 1 min and t = 2 min data expressed by
percentage of control.
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Figure 34. Effects of CaMKK/AMPK Inhibition on AUC values.
Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100
μM. Sample sizes range from 5 to 16. (* indicates P < 0.05)
Bottom Panel: Data expressed as percentage of control.
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Combination Effects with Rho Kinase inhibition
CaMKK/AMPK inhibitor STO-609 was used in concert with Rho
Kinase inhibitor Y27632 to observe any additive effect.

In 7

strips so tested, both 10 μM STO-609 alone and 10 μM STO-609
with 10 μM Y27632 significantly inhibited peak contraction
elicited by 1 μM CCh: 1.57 ± 0.32 grams for Control, 1.31 ± 0.24
grams for STO-609 alone (P < 0.05), 0.89 ± 0.18 grams for both
inhibitors (P < 0.01).

In addition, the contraction elicited by

1 μM CCh in the presence of both inhibitors was significantly
lower than with STO-609 alone (P < 0.05).

There is a

significant additive effect of CaMKK/AMPK inhibition and Rho
Kinase inhibition on peak contraction.
A similar additive effect was seen on AUC values 0-1 min and
0-2 min.

For the 0-1 min AUC metric, control values (in gram-

seconds) were 66.84 ± 14.99 versus 52.24 ± 10.47 for STO-609
alone (P < 0.05, n=7) and 28.17 ± 4.31 for both inhibitors.

The

value in the presence of both inhibitors was significantly less
than with STO-609 alone (P < 0.05, n=7).

For the 0-2 min AUC

metric, control values (in gram-seconds) were 142.6 ± 131.86
versus 122.4 ± 26.22 for STO-609 alone (P < 0.05, n=7) and 68.36
± 9.72 for both inhibitors (P < 0.05, n=7).

The value in the

presence of both inhibitors was significantly less than with
STO-609 alone (P < 0.05, n=7).

These results are visualized in

Figure 35.
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Figure 35. Combined Effects of CaMKK/AMPK and Rho Kinase
Inhibition.
Top Panel: Effects of CaMKK/AMPK inhibition with Rho kinase
inhibition on peak contraction are additive. (n=7, * indicates P
< 0.05).
Middle Panel: Effects of CaMKK/AMPK inhibition with Rho kinase
inhibition on AUC 0-1 min are additive. (n=7, * indicates P <
0.05).
Bottom Panel: Effects of CaMKK/AMPK inhibition with Rho kinase
inhibition on AUC 0-2 min are additive. (n=7, * indicates P <
0.05).
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MLCK activity
The effect of CaMKK/AMPK inhibition on MLCK activity was
measured using immunokinase assay.

MLCK activity was measured

in longitudinal muscle-myenteric plexus (LM-MP) strip
homogenates of four groups: control, following 10 min incubation
of 10 μM STO-609, 1 min post 1 μM CCh exposure, and 1 min post 1
μM CCh exposure following 10 min incubation with 10 μM STO-609.
1 μM CCh increased MLCK activity to 167% ± 21% of control
activity (P < 0.05 versus control, n = 12).

Incubation for 10

min with STO-609 reduced CCh-induced activity to 146% ± 19% of
control activity (P < 0.05 versus control, n = 8).

Incubation

of STO-609 alone did not differ MLCK from control (n = 12 for
control, n = 4 for STO-609 alone).

CCh-induced activity was not

significantly varied between strips with and without CaMKK/AMPK
inhibition (n = 12 for CCh, n = 8 for CCh with STO-609
incubation).

Results are shown in Figure 36.
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Figure 36. Effect of CaMKK/AMPK inhibition on CCh-evoked MLCK
activity.
1 μM CCh-induced MLCK activities with and without CaMKK/AMPK
inhibition are presented.

Values expressed as percentage ± SEM

of control MLCK activity.

Control, n = 12.

CCh-induced

activity is 167% ± 21% of control (P < 0.05, n = 12).

CCh

activity in the presence of 10 μM STO-609 reduces CCh-induced
activity to 146% ± 19% of control (P < 0.05, n = 8).
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Effects of CaMKII Inhibition (KN62)
Incubation of strips for 15 minutes in 10 μM KN62 (a CaMKII
inhibitor) allows for comparison of CaMKII inhibited
contractions to control conditions.

CaMKII inhibition was

viewed from the contractile perspective of basal tone
regulation, peak contraction, contraction at one and two minutes
post CCh exposure, and area under the curve values.

Additive

effects of CaMKII inhibition with Rho Kinase inhibition were
tested.

The effect of CaMKII inhibition on MLCK activity was

studied via molecular methods.

Basal Activity
CaMKII inhibition led to a significant decrease in basal tone
after 10 minutes of incubation.

In studied strips (n=8),

administration of KN62 (CaMKII inhibition) resulted in a change
of basal tone from 0.61 ± 0.07 grams to 0.53 ± 0.07 grams.

A

conducted paired t-test returned P < 0.05; the inhibition of
CaMKII reduces basal tone.

Data summarized and displayed in

Figure 37.

Peak Contraction due to carbachol
CaMKII inhibition (via KN62 incubation) significantly reduced
contraction for all concentrations of carbachol.

Control peak

contraction values (in grams) versus contractions following KN62
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incubation are 0.52 ± 0.14 versus 0.34 ± 0.12 (P < 0.05, n=7) at
10 nM CCh; 0.74 ± 0.10 versus 0.46 ± 0.05 (P < 0.01, n=13) for 1
μM CCh; and 1.35 ± 0.32 versus 0.64 ± 0.15 (P < 0.05, n=7) at
100 μM CCh.

Summary data are displayed in Figure 38.

Contraction at 1 min and 2 min minutes post exposure
CaMKII inhibition reduced the contraction at both 1 min and 2
min post CCh exposure for all concentrations of CCh.

With 10 nM

CCh, 1 minute control values (in grams) versus KN62 incubation
were 0.71 ± 0.07 versus 0.52 ± 0.06 (P < 0.05), 2 minute values
were 0.67 ± 0.07 for control versus 0.51 ± 0.07 for KN62
incubation (P < 0.05, both n=4); for 1 μM CCh, 1 minute control
values (in grams) were 1.28 ± 0.10 versus 0.99 ± 0.11 (P <
0.01), 2 minute values were 1.15 ± 0.1 for control versus 0.94 ±
0.10 grams for KN62 incubation (P < 0.05, both n=11); for 100 μM
CCh, 1 minute control values (in grams) versus KN62 incubation
were 1.33 ± 0.18 versus 0.81 ± 0.08 (P < 0.05, n=5), 2 minute
control values were 1.11 ± 0.16 versus 0.74 ± 0.08 for KN62
incubation (P < 0.05, n=4).

Data summarized in Figure 39.
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Area under curve for first two minutes
CaMKII inhibition caused a significant decrease in the area
under the curve metric in the first (AUC 0-1), second (AUC 1-2),
and first two minutes (AUC 0-2) for contractions elicited by 1
μM and 100 μM CCh.

AUC data for 10 nM CCh contractions were

significantly reduced only for the AUC 0-1 min measurement.

For

AUC 0-1 min, control versus KN62 incubation values (in gramseconds): for 10 nM CCh, 8.59 ± 2.46 versus 5.48 ± 1.44 (P <
0.05, n=5); for 1 μM CCh, 36.98 ± 6.03 versus 20.89 ± 2.89 (P <
0.05, n=11); for 100 μM CCh, 58.47 ± 14.21 versus 33.00 ± 7.09
(P < 0.05, n=7).

For AUC 1-2 min, control versus KN62

incubation values (in gram-seconds): for 10 nM CCh, 11.20 ± 4.73
versus 7.68 ± 3.45 (P > 0.05, n=5); for 1 μM CCh, 36.24 ± 5.62
versus 23.69 ± 3.6 (P < 0.01, n=11); for 100 μM CCh, 46.24 ±
4.25 versus 34.84 ± 3.33 (P < 0.05, n=7).

For AUC 0-2 min,

control versus KN62 incubation values (in gram-seconds): for 10
nM CCh, 22.13 ± 10.10 versus 16.14 ± 7.43 (P > 0.05, n=4); for 1
μM CCh, 69.38 ± 11.85 versus 42.11 ± 5.99 (P < 0.05, n=12); for
100 μM CCh, 100.7 ± 18.58 versus 63.46 ± 10.27 (P < 0.05, n=5).
Summary data for AUC values is presented in Figure 40.
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Figure 37. Effect of CaMKII inhibition on basal tone.
Administration of 10 μM KN62 for 10 min resulted in
significant reduction of basal tone from 0.61 ± 0.07 grams to
0.53 ± 0.07 grams (P < 0.05, n=6).
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* = P < 0.05

146

Figure 38. Effect of CaMKII inhibition on peak contraction.
Top Panel: CaMKII inhibition significantly reduced peak
contraction elicited by 10 nM CCh (0.52 ± 0.14 versus 0.34 ±
0.12, n=7), 1 μM CCh (0.74 ± 0.10 versus 0.46 ± 0.05 grams,
n=13) and by 100 μM CCh (1.35 ± 0.32 versus 0.64 ± 0.15 grams,
n=7. (* = P < 0.05)
Bottom Panel: Summary data expressed as percentage of control.
(* = P < 0.05)
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Figure 39. Effect of CaMKII inhibition on contractions at 1
min and 2 min post CCh exposure.
Top Panel: Tone was reduced at t = 1 min and t = 2 min with
Rho kinase inhibition. Sample Sizes range from 4 to 11. (* = P <
0.05)
Bottom Panel: t = 1 min and t = 2 min data expressed by
percentage of control.
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Figure 40. Effect of CaMKII inhibition on AUC values.
Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100
μM. Sample sizes range from 5 to 16. (* indicates P < 0.05)
Bottom Panel: Data expressed as percentage of control.
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Combination Effects with Rho Kinase inhibition
CaMKII inhibitor KN62 was used in concert with Rho Kinase
inhibitor Y27632 to observe any additive effect.

In 8 strips so

tested, both 10 μM KN62 alone and 10 μM KN62 with 10 μM Y27632
significantly inhibited peak contraction elicited by 1 μM CCh:
0.92 ± 0.09 grams for Control, 0.60 ± 0.05 grams for KN62 alone
(P < 0.05), 0.36 ± 0.06 grams for both inhibitors (P < 0.05).
In addition, the contraction elicited by 1 μM CCh in the
presence of both inhibitors was significantly lower than with
KN62 alone (P < 0.05).

There is a significant additive effect

of CaMKII inhibition and Rho Kinase inhibition on peak
contraction.
A similar additive effect was seen on AUC values 0-1 min and
0-2 min.

For the 0-1 min AUC metric, control values (in gram-

seconds) were 39.64 ± 5.21 versus 24.52 ± 2.67 for KN62 alone (P
< 0.05, n=8) and 11.47 ± 2.89 for both inhibitors.

The value in

the presence of both inhibitors was significantly less than with
KN62 alone (P < 0.05, n=8).

For the 0-2 min AUC metric, control

values (in gram-seconds) were 80.97 ± 11.84 versus 51.43 ± 4.00
for KN62 alone (P < 0.05, n=8) and 34.70 ± 3.18 for both
inhibitors (P < 0.05, n=8).

The value in the presence of both

inhibitors was significantly less than with KN62 alone (P <
0.05, n=7).

These results are summarized in Figure 41.
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Figure 41.

Combined Effects of CaMKII and Rho Kinase
inhibition.

Top Panel: Effects of CaMKII inhibition with Rho kinase
inhibition on peak contraction are additive. (n=8, * indicates P
< 0.05).
Middle Panel: Effects of CaMKII inhibition with Rho kinase
inhibition on AUC 0-1 min are additive. (n=8, * indicates P <
0.05).
Bottom Panel: Effects of CaMKII inhibition with Rho kinase
inhibition on AUC 0-2 min are additive. (n=8, * indicates P <
0.05).
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MLCK activity
The effect of CaMKII inhibition on MLCK activity was measured
using immunokinase assay.

MLCK activity was measured in

longitudinal muscle-myenteric plexus (LM-MP) strip homogenates
of four groups: control, following 10 min incubation of 10 μM
KN62, 1 min post 1 μM CCh exposure, and 1 min post 1 μM CCh
exposure following 10 min incubation with 10 μM KN62.

1 μM CCh

increased MLCK activity to 167% ± 21% of control activity (P <
0.05 versus control, n = 12).

Incubation for 10 min with Y27632

reduced CCh-induced activity to 140% ± 14% of control activity
(P < 0.05 versus control, n = 8).

Incubation of KN62 alone did

not differ MLCK from control (n = 12 for control, n = 3 for KN62
alone).

CCh-induced activity was not significantly varied

between strips with and without Rho Kinase inhibition (n = 12
for CCh, n = 8 for CCh with KN62 incubation).
in Figure 42.
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Results are shown

Figure 42. Effect of CaMKII inhibition on CCh-evoked MLCK
activity.
1 μM CCh-induced MLCK activities with and without Rho Kinase
inhibition are presented.

Values expressed as percentage ± SEM

of control MLCK activity.

Control, n = 12.

CCh-induced

activity is 167% ± 21% of control (P < 0.05, n = 12).

CCh

activity in the presence of 10 μM KN62 reduces CCh-induced
activity to 140% ± 14% of control (P < 0.05, n = 8).
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DISCUSSION
Strip Generalities
The strips obtained and studied were fairly consistent in
their responses to carbachol and the kinase inhibitors used.
Two distinct behavior patterns were noted – those with an early
peak and moderate decay and those that displayed a slow rise of
tension.

Strips of each subpopulation were appropriately

utilized. It is important before the data is explored and
interpreted to make a distinction between the behaviors of these
muscle strips, and, for the most part, data from biochemical
assays completed on isolated muscle cells.

Whereas the assays

done in smooth muscle cells (particularly cultured cells) have
as their samples uniform biochemical consistency and homogenous
population, strips perform as functional tissue, with many
different cell types.

These strips have cells bound to

extracellular matrix, orienting the cells in an organized
fashion and altering their functional abilities as a whole.
These strips of tissue may have some connective tissue attached
and certainly have attached the myenteric plexus which can alter
both the response of the strips to agents and the composition of
any homogenate, as compared to a homogenate of isolated muscle
cells.

Differences in the possible amount of nerve tissue

present or the tying/mounting of a particular strip could
certainly affect the homogenate composition or the basic
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contractile behavior of a given strip.

However, since each

strip serves as its own control when performing comparisons to
the effects of inhibitors/blockers, these differences in strip
behavior/composition are minimized.

Grand Means
Since there is variance within the performance of strips under
control conditions, mean values of the utilized metrics were
studied.

The contractile response to carbachol of strips is

concentration dependent as seen in Figure 11; there is some
range of contractile values obtained.

This is primarily a

consequence of the reporting of tension as grams and not as
grams per gram of tissue.

Similar ranges of values are seen in

the t = 1 min and t = 2 min values (Figure 12) and the area
under the curve (AUC) values for the first, second, and first
two minutes (Figure 13).

These ranges also could have been

minimized through normalization by mass; nonetheless, the use of
a given strip as its own control enables the appropriate use of
the dependent t-test (repeated measurement dependence).
Sizable, measured differences can be certified significant even
if the range of data suggests otherwise.

Findings not found

significant under these conditions can be viewed in the same
manner – it is more likely that an effect is not present, than
it is that significance was clouded by data variability.
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Repeated Measures
Once mounted, strips spend considerable time equilibrating in
bath solutions.

This occurs following the initial mounting and

immersion, as well as after washes to remove agonist or
antagonist.

So that the effects of the long term presence of

strips can be eliminated as a factor in any change in their
behavior, measurements similar to those conducted in the
presence of inhibitor were performed on strips incubated only in
standard Krebs solution.

Figure 14 and Figure 15 demonstrate

that after a 15 min incubation period, there is no significant
effect on strip performance following incubation.

Any effects

of incubation on strip behavior are consequences of the presence
of inhibitor in the bath, not the fatigue/deterioration of the
strip.

Muscarinic Antagonism
Both M2 and M3 receptors are prevalent in muscle tissue, and
the literature shows a higher density of M2 receptors, but a
greater functional role of M3 receptors [86].

Modulation of

contraction by both types of receptors has been studied, with
some studies asserting no necessary role of M2 or M3 receptors in
smooth muscle contraction [84, 165].

Data displayed in Figure

16 strengthens the idea that M3 receptor activity is critical for
the contractile behavior that this study measures.

Blockade of

M2 causes little effect in CCh-induced contraction; such
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contraction is abolished by M3 blockade.

Published data

implicates M1 receptors in human colonic myenteric plexus [166].
As these receptors are localized to nerves, neural contributions
to observed contractile behaviors should be addressed.

Effects of Neural Inhibition
The effects of the attached plexus to strips may be the reason
differences between strip behavior and isolated muscle cell
behaviors are seen.

Such differences in isolated cell/intact

strip behavior have been reported – the presence of nerve in the
strip was the explanation for observed differences [10]. Nerves
constitute a minor percentage of the mass of intact muscle, but
in this preparation, the mass percentage of nerve tissue may no
longer be trivial.

Tissue homogenates could have a substantial

neural homogenate component.

Treatment of strips with TTX

following control CCh contractions allows for this effect to be
determined.

As shown in Figure 17, TTX incubation has no

significant effect on the contractions induced by carbachol,
although the data does trend to more contraction with TTX
incubation.

Such a finding would not be in conflict with the

literature – longitudinal muscle possesses innervation pathways
populated with many inhibitory interneurons [11].
inhibition could be relieved by TTX.

This

Figure 18 and Figure 19

demonstrate similar effects of TTX on t = 1 min and t = 2 min
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data, as well as on AUC values.

Again, AUC values did appear to

trend higher, suggesting removal of inhibitory input by TTX.

Kinase Inhibition Housekeeping
The following table summarizes the findings of kinase
inhibition on the contractile behavior of strips.

The tabular

format allows for later comparisons between kinases to be made.
Peak and AUC data are expressed as percentages of control ± SEM.
Sample sizes can be found in the results section.

The reader is

directed to Figures 22, 27, 33, and 39 in the results section
for the percentage values of t = 1 min and t = 2 min
experiments.
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Table 1. Tabular representation of peak and AUC data for
kinase inhibition experiments.
Values represent percentage of control.

Sample sizes to be

found in results section. Italics indicate P < 0.05, based on ttest of original raw data.
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Rho Kinase
Inhibition

ERK1/2
Inhibition

CaMKK/AMPK
Ihibition

CaMKII
Inhibition

10 nM CCh

70 ± 13

60 ± 5

64 ± 7

70 ± 6

1 μM CCh

62 ± 9

64 ± 6

67 ± 5

66 ± 6

100 μM CCh

58 ± 8

65 ± 4

71 ± 7

51 ± 9

10 nM CCh

37 ± 5

60 ± 7

59 ± 4

65 ± 4

1 μM CCh

33 ± 4

60 ± 6

73 ± 3

61 ± 9

100 μM CCh

50 ± 8

65 ± 4

70 ± 9

62 ± 6

10 nM CCh

32 ± 4

60 ± 4

67 ± 6

67 ± 5

1 μM CCh

37 ± 4

59 ± 9

74 ± 4

61 ± 9

100 μM CCh

62 ± 12

55 ± 4

73 ± 7

72 ± 4

10 nM CCh

32 ± 6

64 ± 6

65 ± 3

69 ± 8

1 μM CCh

37 ± 4

55 ± 4

74 ± 4

63 ± 8

100 μM CCh

55 ± 8

61 ± 3

71 ± 7

67 ± 5

Peak

AUC 0-1 min

AUC 1-2 min

AUC 0-2 min
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Effects of Rho Kinase Inhibition
In this study, inhibition of Rho kinase led to significant
decreases in basal tone (Figure 20), peak contraction (Figure
21), contraction at 1 and 2 minutes post CCh administration
(Figure 22), and AUC values (Figure 23).

Rho kinase is known to

promote MLC20 phosphorylation (and contraction) through its
phosphorylation of MYPT1, regulating contraction through
inhibition of MLCP.

Rho kinase is also implicated in the

activation of CPI-17, another MLCP inhibitor [73, 74, 167].

Rho

kinase inhibition should have an obvious effect in promoting
contraction, but its role seems more important in maintaining a
sustained contraction, as its expression is heightened in tonic
smooth muscle [112, 168].

Although Rho kinase inhibition shows

decreases in tone as compared to control at t = 1 min, and t = 2
min (Figure 22), when these data are viewed as percentages of
the control contraction, it can be inferred that this sustained
phase may not be appreciably reduced – the initial contraction
was smaller, so contraction values at t = 1 min and t = 2 min
are obviously reduced, and the “sustained phase” similar to
control.

In this study, the more obvious finding is that Rho

kinase is demonstrating an acute effect.

Peak contractions are

reduced, at a similar level (slightly greater) than the other
inhibitors.
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The literature as a whole focuses upon Rho kinase as a
modulator of sustained contraction.

Mbikou observed an acute

effect of Rho kinase on contraction in airway smooth muscle,
similar to findings of this study [169].

Frei found that the

common Rho kinase inhibitor used in this study, Y27632, had no
effect upon reducing CCh-induced contraction in colonic
longitudinal muscle – the data of this study suggests a sizable
effect [170].

The phosphorylation of MYTP1 and CPI-17 by Rho

kinase can only aid in maintaining a level of tone; their
inhibition (through Rho kinase inhibition) could not present
itself as a decrease in induced contraction.

From the

perspective of phosphatase inhibition via Rho kinase, incubation
with Y27632 would increase basal phosphatase activity – MLC20
phosphorylation would be decreased in resting state.

Here,

Y27632 incubation causes a decrease in basal tone but a
reduction of peak contraction.

Something else must be mediating

this acute effect.
Hagerty offers a mechanism whereby Rho kinase increases the
activity of ZIP kinase, known to effect Ca2+-independent MLC20
phosphorylation [99, 115]. This is supported by Ihara and
MacDonald, who find direct phosphorylation of MLC20 by ZIP kinase
as well as phosphorylation of MYPT1 by ZIP kinase, which is the
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possible mechanism connecting Rho kinase to its phosphorylation
actions on the protein MYPT1 [75, 171, 172].
Another possibility is direct phosphorylation of MLC20 by Rho
kinase.

When Rho kinase is activated by Rho following M3

activation, direct phosphorylation of MLC20 could take place.
Inhibition of this possible phosphorylation mechanism would
present itself as an acute effect.

Such phosphorylation of MLC20

by Rho kinase has been reported [113].

The same group has

implicated Rho kinase as an upstream mediator of a pathway that
regulates nitric oxide production through eNOS in endothelial
cells [114].

Although the muscle strips of this study possess

no endothelial cells to generate NO, the nerves of the attached
myenteric plexus are known to do so [11].
As compared to the other kinases, Rho kinase inhibition caused
a far larger inhibition of all AUC values, and peak values
except for those at the 10 nM CCh level.

This may indicate an

acute effect as evidenced by the reduced peak contraction.

In

addition, inhibition of the other kinases reduces the peak
contraction by factor similar to their reduction in AUC values.
Rho kinase inhibition causes far more reduction in AUC values as
compared to its effect on the peak contraction.
hybrid/combined effect exists.
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Possibly a

Effects of ERK1/2 Inhibition
Influence of ERK1/2 in smooth muscle contractile regulation is
widely displayed in the literature.

ERK1/2 is reported to have

a presence in pathways of pathophysiological smooth muscle,
either through its ability to phosphorylate directly a pertinent
substrate or by its transcription factor behavior [87, 118].

It

has roles in desensitization pathways in gastric smooth muscle
and mediates contraction in vascular smooth muscle through
endothelin signaling [119, 162].

ERK1/2 signaling can also be

increased by muscarinic activation in a manner that increases
cPLA2, a critical enzyme in longitudinal muscle calcium handling
[120].

Its activity seems to be connected to contraction;

ERK1/2 inhibition reduces contraction in this study and others
[172].
ERK1/2 inhibition in this study produces a reduction in both
peak contractile values and AUC values (Figure 26 and Figure
28).

The degree of inhibition is second only to Rho kinase.

ERK1/2 inhibition caused predictable concomitant decrease in
contraction at t = 1 min and t = 2 min (Figure 27), with similar
percentage of peak profiles as control. With ERK1/2
signaling/activity playing an established role in contractile
regulation, its potential targets fall into several categories.
Harnett verifies ERK1/2 phosphorylation of integrin-linked
kinase (ILK) in esophagus, Muranyi links ILK to Ca2+-independent
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contraction via MYPT1 phosphorylation, and Deng offers direct
phosphorylation of MLC20 by ILK [78, 81, 82].

Therefore ERK1/2

can be connected to actions on MLC20 directly and through
phosphatase inhibition.

Morrison from a biochemical standpoint

and Klemke from a cell motility/proliferation angle both
demonstrate that ERK1/2 directly phosphorylates MLCK and that
this phosphorylation enhances MLCK activity [65, 66].

Others

show similar effects that ERK1/2 can have modulatory effects on
the MLCK as well.

Immunokinase assay data from this study

suggests a possible enhancement by ERK1/2.

In addition to MLC20,

MYPT1, and MLCK modulation, ERK1/2 is also known to
phosphorylate accessory proteins in the contractile mechanism or
cytoskeleton.

Both caldesmon and calponin are targeted by

ERK1/2 [54, 117].
In conjunction with Rho kinase inhibition, ERK1/2 inhibition
produced no additive reduction of contraction (Figure 29).

This

can be considered either a consequence of their shared effects
upon MYPT1 phosphorylation (which does speak more to sustained
aspects) or that the inhibition of peak contraction by ERK1/2
inhibition is mediated through its effects on direct
phosphorylation of MLC20 via ILK, duplicated by the same actions
through Rho kinase via ZIP kinase.

Yet, it is more likely that

an additive effect should exist, considering all avenues of
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inhibition that ERK1/2 possesses, and that careful
experimentation would illuminate these.

Effects of CaMKK/AMPK Inhibition
AMPK has implications in cellular metabolism in cells/tissues
with metabolic needs that may have large variations with
activity, such as muscle.

Studies from tetanic electrical

stimulation to hibernation to osmotic stress establish AMPK as a
regulator/”switch” of glucose uptake, lipid metabolism, and
mitochondrial manipulation [135, 142, 173].

CaMKK is an

upstream effector of AMPK activity, with the beta isoform of
CaMKK as the particular modulating kinase [134, 139].

This

regulation of AMPK can be mediated through M3 activation [136].
However, the upstream regulation of AMPK by CaMKK is time
dependent.

After sustained activation of AMPK by CaMKK,

blockade of CaMKK no longer can affect AMPK activity in a model
of tetanic contraction [174].

In addition, the alpha isoform of

CaMKK does not modulate AMPK activity as it relates to metabolic
processes [138].

The inhibitor used in this study (STO-609)

targets both isoforms of CaMKK for inhibition, so use of this
inhibitor does have consequences beyond AMPK [140, 141].
As a regulator of contraction, both Horman and Al-Shboul have
shown that AMPK activity leads to phosphorylation of MLCK kinase
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in a manner that reduces its ability to foster contraction [143,
175].

Bultot demonstrates that AMPK can directly phosphorylate

MLC20, but that such is unlikely to be its proper physiological
function [144].

In this study, inhibition of CaMKK activity was

found to reduce peak contraction and AUC values (Figure 32 and
Figure 34).

CaMKK inhibition caused predictable concomitant

decrease in contraction at t = 1 min and t = 2 min (Figure 33),
with similar percentage of peak profiles to control.

MLCK

activity was also decreased with CaMKK inhibition (Figure 36).
Also, additive effects of CaMKK inhibition with Rho kinase
inhibition were observed, implicating CaMKK effects on the
kinase side of MLC20 phosphorylation regulation (Figure 35).
These data are in conflict with Al-Shboul and Horman.

Al-

Shboul, however, made his findings in isolated circular muscle
cells (no neural input) and Horman in chicken gizzard, a
muscular structure with smooth muscle and innervation but little
similarity to longitudinal muscle in gut.

The findings of this

study are in a model of different muscle type and are from
strips, which may contract with different regulation than
isolated cells (Al-Shboul) or have a different neural
contribution as a homogenate for MLCK assay (Horman).
Furthermore, studies by Donsmark and Blair show that AMPK
activity increases with electrically stimulated contraction
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[176, 177].

It is conceivable that AMPK activity increases as a

consequence of contraction, not as a modulator of contraction,
but to evoke the metabolic modulatory effects in tissue whose
metabolic needs have been advanced.

The current study also used

an inhibitor (STO-609) which does not discriminate between the
alpha and beta isoforms.

Only the beta isoform is an effector

of AMPK, and any independent effects CaMKK may have on
contraction would be simultaneously affected.

Schmitt shows

ERK1/2 activation by CaMKK via calcium-calmodulin dependent
kinase I (CaMKI), and this study has established the importance
of ERK1/2 signaling in longitudinal muscle.
would affect this negatively [178].

CaMKK inhibition

Lastly, like CaMKII, this

enzyme is dependent on calcium-calmodulin interactions for
regulation of its activity, and with the unique calcium handling
of longitudinal muscle, could conceivably have different effects
as a result of different calcium dynamics.

Effects of CaMKII Inhibition
In this study, CaMKII inhibition by KN62 incubation caused
decreases in basal tone (Figure 37), peak tension development
(Figure 38), and AUC values (Figure 40). CaMKII inhibition
caused predictable concomitant decrease in contraction at t = 1
min and t = 2 min (Figure 39), with similar percentage of peak
profiles to control.

CaMKII inhibition resulted in a decrease
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of CCh-induced MLCK activity (Figure 42).

These data are in

conflict with Murthy, who found that CaMKII inhibition reduced
MLCK activity and Tansey who found KN62 causes a decrease in
calcium sensitization of MLCK, reducing its activity [84, 129].
Both of these studies were in isolated cells of muscle types
(circular muscle, tracheal muscle) who differ in characteristics
from longitudinal muscle.

Hashimoto found that CaMKII can

phosphorylate MLCK as a negative effector (in conflict the
presented data), but that such phosphorylation could only occur
before binding of calcium-calmodulin to MLCK [130].

As with

CaMKK, differences in calcium handling in longitudinal muscle
might preclude this effect, and the Hashimoto experiment was
performed with purified protein (both MLCK and CaMKII).

The

additive effects of CaMKII inhibition with Rho kinase inhibition
(Figure 41) suggests effects of CaMKII exist on kinase leg of
regulation.
Studies by Henning and Pauly expose CaMKII as critical in the
processes of migration and hypertrophy, where positive
associations with myosin are more often observed than
associations that decrease activity or important cooperative
binding [125, 126].

Edelman and Kim demonstrate direct

phosphorylation of MLC20 with CaMKII activation, which would
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agree with the findings of decreased basal tone with incubation
of CaMKII inhibitor (Figure 37) [132, 179].
CaMKII also has modulatory effects on ion channels and SR
which would present heightened importance given the calcium
handling modality of longitudinal muscle.

McCarron implicates

CaMKII in calcium channel regulation as a possible feed-forward
mechanism, increasing calcium influx with CaMKII activity [180].
Greenwood shows that regulation of ion channels by CaMKII can
differ between arterial and venous smooth cells [121].

It

remains conceivable that calcium channel regulation could be
different in longitudinal muscle (versus circular) where such
effects would have larger consequences on calcium mobilization.
Moreover, CaMKII can modulate SR receptors.

Witcher finds

that CaMKII phosphorylation of cardiac ryanodine receptors leads
to enhanced calcium release.
skeletal muscle [127].

This effect is not seen in

Given the similarities of calcium

handling in cardiac and gut longitudinal muscle, such inhibition
of CaMKII would reduce calcium mobilization and contractile
activity, as findings in this study demonstrate.
is an obvious upstream effector of ERK1/2.

Lastly, CaMKII

Marganski shows an

essential role of CaMKII in regulation of downstream ERK1/2
activity [124].

ERK1/2 importance in contractile regulation in

colonic longitudinal muscle has been established by the current
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findings.

Blockade of CaMKII would affect contraction in a

manner similar to ERK1/2 regulation, and this is in concert with
these data.
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Putative Longitudinal Model
Because the contrary effects of CaMKK and CaMKII inhibition as
compared to the circular muscle model (Figure 2), an updated
model is offered for longitudinal muscle.

The effects of CaMKK

and CaMKII upon ERK1/2 activation, ion channels, SR receptors,
and MLC20 phosphorylation have been added.

The new model is

offered in Figure 43, and both models together in Figure 44.
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Figure 43. Model for Longitudinal Muscle Regulation.
Open Triangles indicate legacies of putative circular model
roles of CaMKK/AMPK and CaMKII.

Arrows indicate positive

regulation.

178

179

Figure 44. Circular and Longitudinal Muscle Regulation by
Kinases.
Top Panel: Putative circular muscle model.
Bottom Panel: Putative longitudinal muscle model. Open
triangles indicate contrary legacies from circular model.
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Avenues to Explore
To further and strengthen the model, the following experiments
are proposed:


Western Blot analysis to observe MLC20 phosphorylation
levels directly under control conditions and in response to
CCh, with and without kinase inhibition.



Kinase assays for these candidate kinase, as well as ZIPK
and ILK.

These assays could offer information regarding

Ca2+-independent contraction regulation, and with
appropriate use of inhibitors could sequence any possible
cascades.


Exploration of phosphatase activity by these kinases.

This

could be accomplished indirectly through observation of
phosphorylation/activation of phosphatase inhibitors MYPT1
and CPI-17


Experiments with kinase inhibition in conjunction with
muscarinic antagonism and Na+ channel blockade via TTX, to
determine neural contributions and possible modulation by M2
signaling.



Combination of kinase inhibition on contraction to
determine possible additive effects or redundancies.
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